{"id":90989,"topic":"ai","source":"生物通","title":"人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","url_hash":"a24c607e641008926d6fe2f24f7f9232b3946e4c","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMibEFVX3lxTE1tZVVBc0N3U0pPR01Oc1pXU25mVnM3c2hLdkRFMUU4TEtiVVNfTmU4aHFTelZneVRuY1FVRkxWakIyWi04N01CZGtaUlVJNkFLRERfVExQdXJLbndFS01UTDJzdGVuUVFZWUFCdw?oc=5\" target=\"_blank\">人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">生物通</font>","content":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ·ÅÉä¿Æҽʦ33.3%£©£¬×÷Ϊ¸¨Öú¹¤¾ßʱÁéÃô¶ÈÏÔÖøÌá¸ß£¨Ê¹ÓÃAI 41.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs. 135, p<0.001£©¡£RauscheckerµÈÈËÆÀ¹ÀÁ˽áºÏDLºÍ±´Ò¶Ë¹ÍøÂçµÄMRI¼ø±ðÕï¶ÏAIϵͳ£¬Ëã·¨´ïµ½91%µÄÇ°ÈýλÕï¶Ï׼ȷÂÊ£¬±íÏÖÓëѧÊõÉñ¾·ÅÉä¿ÆҽʦÏ൱£¨86%; p=0.20£©£¬ÓÅÓÚסԺҽʦ£¨56%; p<0.001£©¡¢½øÐÞҽʦ£¨77%; p=0.003£©ºÍÆÕͨ·ÅÉä¿Æҽʦ£¨57%; p<0.001£©¡£\n4.2 ÁÙ´²ÊµÊ©Ó빤×÷Á÷³ÌÓ°Ïì\nÔÚ¼±ÐÔÉñ¾Ó°ÏñѧÖУ¬»ùÓÚCNNµÄÄ£ÐÍÔÚ´óѪ¹Ü±ÕÈû£¨Large Vessel Occlusion, LVO£©×äÖмì²âÖдﵽ85%µÄÁéÃô¶È£¬ÏÔÖøÓÅÓÚËæ»úÉÁÖÄ£ÐÍ£¨68%£©£¬²¢¾ßÓмÓËÙ·ÖÕïºÍÖÎÁÆʱ¼äÏßµÄDZÁ¦¡£RAPID ICH¡¢Viz.aiºÍAldoc MedicalµÈ¹¤¾ßÀûÓÃDL×Ô¶¯Ê¶±ðºÍ·ÖÀàCTÉϵijöѪ£¬×÷ΪʵʱÕï¶Ï¸¨Öú£¬Ìṩ¡°¶þ´ÎÔĶÁ¡±¡¢ÐÖúÖÊÁ¿±£Ö¤²¢°ïÖú·ÅÉä¿ÆҽʦÓÅÏÈ´¦Àí½ô¼±²¡Àý£¬¿ÉÄܼõÉÙÅжÁÑÓ³Ù¡£\n4.3 ÕæʵÊÀ½ç²ÉÓÃÓëÓû§ÈÏÖª\nº«¹ú·ÅÉä¿Æҽʦȫ¹úµ÷²éÏÔʾ£¬60.3%£¨223/370£©Òѽ«»ùÓÚAIµÄÈí¼þÄÉÈëʵ¼ù£¬Ö÷ÒªÓÃÓÚ²¡Ôî¼ì²â£¨82.1%£©¡¢Õï¶Ï¸¨Öú£¨55.2%£©ºÍͼÏñ·ÖÀࣨ55.2%£©¡£67.6%µÄÊÜ·ÃÕß×¢Òâµ½»¼Õß¹ÜÀíµÄ¸ÄÉÆ£¬85.1%¶ÔAIÐÔÄܱíʾ×ÜÌåÂúÒ⡣Ȼ¶ø£¬92%µÄÊÜ·ÃÕßÈÏΪÐèÒªÕý¹æ½ÌÓýºÍÖ¸ÄÏÒÔÈ·±£AIÊä³öµÄÊʵ±Ê¹Óúͽâ¶Á¡£\n4.4 ÁÙ´²½á¾Ö×ܽá\nÔÚ¶à¸öÁìÓò£¬AIÇý¶¯µÄÉñ¾Ó°ÏñϵͳչÏÖ³ö¸ßÕï¶Ï׼ȷÐÔ¡¢Ð§ÂʺͿÉÀ©Õ¹ÐÔ£¬ÐÔÄܳ£Óëר¼ÒÉñ¾·ÅÉä¿ÆҽʦÏ൱¡£ÆäÁÙ´²ÕûºÏÌṩÁ˼ò»¯¹¤×÷Á÷³Ì¡¢Ö§³Ö¾ö²ßºÍ¸ÄÉÆ»¼Õß½á¾ÖµÄ»ú»á¡£È»¶ø£¬ÕâЩÒæ´¦ÒÀÀµÓÚÑϸñµÄ¶àÖÐÐÄÑéÖ¤ÒÔ¼°¶Ô¿É½âÊÍÐÔ¡¢ÁÙ´²Ò½Ê¦½ÌÓýºÍÂ×ÀíÖÎÀíµÄ³ÖÐø¹Ø×¢¡£\n5 Â×Àí¿¼Á¿Óë¾ÖÏÞÐÔ\n5.1 Êý¾ÝÒþ˽ÓëÖÎÀí\nÊý¾ÝÒþ˽ÊÇAIÇý¶¯Éñ¾Ó°ÏñÖÐ×î½ôÆȵÄÂ×Àí¹ØÇÐÖ®Ò»£¬ÓÈÆäÊǵ±´óÐÍÓ°ÏñÊý¾Ý¼¯´æ´¢ÔÚ¿ç¹ú¼Ê±ß½ç¾ÛºÏÐÅÏ¢µÄÃÅ»§»òÔÆϵͳÖÐʱ¡£ÄÔ²¿É¨Ãè¾ßÓжÀÌØ·çÏÕ£¬ÒòΪ½âÆʽṹ¿ÉÓë¸öÈËÊý¾ÝÆ¥Åä´Ó¶øʵÏÖÔÙʶ±ð¡£Å·ÃËͨÓÃÊý¾Ý±£»¤ÌõÀý£¨GDPR£©Çø·Ö¸öÈËÊý¾Ý¡¢È¥±êʶ»¯Êý¾ÝºÍÍêÈ«ÄäÃûÊý¾Ý£¬¶øÖйú¸öÈËÐÅÏ¢±£»¤·¨£¨PIPL£©½«ÉúÎïʶ±ðºÍÒ½ÁÆÐÅÏ¢¹éÀàΪ¸ß¶ÈÃô¸ÐÊý¾Ý¡£È»¶ø£¬¹ú¼ÒºÍ»ú¹¹¼äÒþ˽·¨ÂɵÄÒìÖÊÐÔʹ¿ç¾³Êý¾Ý¹²Ïí¸´ÔÓ»¯¡£Áª°îѧϰ£¨FL£©Äܹ»ÔÚÎÞÐè´«ÊäÔʼÊý¾ÝµÄÇé¿öϽøÐпç»ú¹¹Ä£ÐÍѵÁ·£¬¼õÉÙ¼¯Öд洢¿âµÄÐèÇó¡£Êý¾ÝʹÓÃÐÒ飨Data Use Agreements, DUAs£©ºÍÊý¾Ý´«ÊäÐÒ飨Data Transfer Agreements, DTAs£©µÈÕýʽÐÒ鶨ÒåÁËÔðÈβ¢·ÀÖ¹ÀÄÓá£\n5.2 żȻ·¢ÏÖÓë¿É½âÊÍÐÔ\nżȻ·¢ÏֵĹÜÀí¡ª¡ªÑо¿»òÕï¶ÏÓ°ÏñÖз¢ÏÖµÄÒâÍâÒì³£¡ª¡ªÌá³öÁËÁíÒ»Â×ÀíÀ§¾³¡£AIϵͳÒò¸ßÁéÃô¶ÈºÍÐí¶àDLÄ£Ð͵ġ°ºÚÏ䡱ÌØÐÔ¶ø¼Ó¾çÁËÕâÒ»ÎÊÌ⣬ÏÞÖÆÁËÁÙ´²Ò½Ê¦½â¶ÁËã·¨ÍÆÀíµÄÄÜÁ¦¡£AIϵͳµÄ¿ª·¢ÕßÓ¦·ÅÆúÓÅÏÈ¿¼ÂÇÉÌÒµÃØÃܶø·Ç͸Ã÷ÐԵġ°ÒþÐοÆѧ¡±×ö·¨¡£¿ª·¢Õß±ØÐëÈ·±£³ÖÐø¼à²âºÍƵ·±ÓÅ»¯AIϵͳ£¬ÒÔ¸úÉϲ»¶Ï·¢Õ¹µÄÁÙ´²Êµ¼ù¡£ÁÙ´²Ò½Ê¦ÔÚ½«ÕâЩ¹¤¾ßÕûºÏµ½ÁÙ´²Êµ¼ùÖÐʱÐèÒª²Éȡƽºâ·½·¨£¬Í¬Ê±²»Ëðº¦ÆäÁÙ´²Åжϡ£½«Î±Ó°»òÕý³£±äÒìÎóʶ±ðΪ²¡Àí¿Éµ¼Ö»¼Õß½¹ÂÇ¡¢²»±ØÒªµÄËæ·Ã¼ì²é»òÎóÕï¡£¸÷˾·¨¹ÜϽÇø¼à¹Ü¿ò¼ÜµÄ²»Ò»ÖÂÐÔʹµÃ½¨Á¢±ê×¼»¯³ÌÐòÀ´¹ÜÀíÕâЩ·¢ÏÖ±äµÃÀ§ÄÑ¡£\n5.3 Ë㷨ƫ¼ûÓ빫ƽÐÔ\nË㷨ƫ¼ûÊÇAIÔÚÉñ¾Ó°ÏñÖÐÂ×ÀíÓ¦Óõĸù±¾¾ÖÏÞ¡£Ò»Ïî½üÆÚÜöÝÍ·ÖÎö·¢ÏÖ£¬97.5%µÄѵÁ·Êý¾Ý¼¯À´×Ô¸ßÊÕÈë»òÖиßÊÕÈëµØÇø£¬µ¼ÖÂϵͳÐÔȱ·¦¶àÑùÐÔ£¬Ï÷ÈõÁËÈ«ÇòÊÊÓÃÐÔ¡£Ò»ÏîAIÕï¶Ï°¢¶û´Äº£Ä¬²¡µÄÑо¿ËµÃ÷ÁËÕâһЧӦ£ºÔÚÃÀ¹ú°¢¶û´Äº£Ä¬²¡Éñ¾Ó°Ïñѧ³«Ò飨Alzheimer's Disease Neuroimaging Initiative, ADNI£©Êý¾Ý¼¯ÉÏѵÁ·µÄCNNÔÚ°Ä´óÀûÑÇAIBL¶ÓÁÐÖбíÏÖÁ¼ºÃ£¬µ«ÔÚÒâ´óÀûI-ADNIÊý¾Ý¼¯ÉÏÏÔÖø¶ñ»¯£¬×¼È·ÂʽöΪ78%¡£Ðí¶àÓÃÓÚAI¿ª·¢µÄ»ùÓÚ»úÆ÷ѧϰ£¨Machine Learning, ML£©µÄÊý¾Ý¿âÀ´×Ô¸ßÊÕÈë¹ú¼Ò£¨Å·Ö޺ͱ±ÃÀ£©£¬¶ÔÑÇÖÞ¡¢À¶¡ÃÀÖ޺ͷÇÖÞÈËȺµÄÄÉÈëÓÐÏÞ£¬Ôì³É¡°Ã÷È·µÄselection bias¡±¡£Ó¦Öƶ¨Õþ²ßÇ¿ÖÆÄÉÈëÖÖ×å¡¢Ãñ×å¡¢ÄêÁä¡¢ÐÔ±ðºÍÉç»á¾¼ÃµØλµÈÈË¿Úͳ¼Æѧ±äÁ¿ÒÔ½øÐÐÆ«¼ûÉó¼Æ¡£Ó¦²ÉÓÃFUTURE-AIÖ¸ÄϵÈÂ×Àí×¼Ôò£¬È·±£¹«Æ½ÐÔºÍÆÕ±éÐÔÔÔòÈÚÈ뿪·¢¹ý³Ì¡£ÃÀ¹ú¡°All of Us¡±Ñо¿¼Æ»®µÈ¿É×÷Ϊ³¬Ô½µØÀíºÍÉç»á¾¼Ã±ß½ç´´½¨È«ÇòÊý¾Ý¿âµÄÄ£ÐÍ¡£\n5.4 ¼à¹ÜÓëʵ¼ù¾ÖÏÞÐÔ\nÏÖÐмà¹Ü»·¾³ÉÐδÊÊÓ¦¶àÖÐÐÄAIÑо¿µÄ¸´ÔÓÐÔ¡£¹ÜÀíÁÙ´²Êý¾Ý¼¯ÊÕ¼¯¡¢Ê¹Óúͽ»»»µÄÉç»á·¨ÂÉ¿ò¼Ü²îÒì×è°Á˹ú¼ÊºÏ×÷¡£´ËÍ⣬Õë¶Ô³ÖÐø´ÓÐÂÊý¾ÝѧϰµÄ×ÔÊÊÓ¦Ëã·¨µÄÉÏÊкó¼à²â»òÑéÖ¤±ê×¼»¯³ÌÐòºÜÉÙ¡£È±·¦È«Ãæ¼à¶½Ê±£¬Â×ÀíºÍ°²È«Ê§Îó¿ÉÄÜÔÚ»¼ÕßÉ˺¦·¢ÉúÇ°²»±»·¢ÏÖ¡£\n5.5 ·¨ÂÉÔðÈÎ\nAI¸¨ÖúÉñ¾Ó°ÏñµÄÁíÒ»¸ö¹ØÇÐÊÇ·¨ÂÉÔðÈΣ¬ÒòΪҽʦ³Ðµ£Õï¶ÏÔðÈΡ£ÔðÈα»ÊÓΪÁÙ´²Ò½Ê¦ÓëË㷨ϵͳ֮¼äµÄ·Ö²¼Ê½¹¹½¨£¬·´Ó³ÁËÁÙ´²Êµ¼ùÖÐÏò¹²Ïí¾ö²ß·¶Ê½µÄת±ä¡£Îª½µµÍ·¨ÂÉ·çÏÕ£¬ÁÙ´²Ò½Ê¦±ØÐëÈ·±£AIµÄʹÓ÷ûºÏͬһר¿ÆºÏ¸ñ´ÓÒµÕߵıê×¼»¤Àíˮƽ¡£·¨ÂÉ·ÖÎö¿¼ÂÇÁ½ÖÖÇéÐΣºÒ»ÊÇҽʦ¾Ü¾øÁË·ûºÏ±ê×¼»¤ÀíµÄÕýÈ·½¨Ò飻¶þÊÇҽʦ×ñÑÁ˲»·ûºÏ±ê×¼»¤ÀíµÄ´íÎóAI½¨Òé¡£Èç¹ûAIÄܳ¬Ô½ÈËÀà¾ö²ßÄÜÁ¦£¬·¨ÂÉר¼ÒÔ¤²â¿ÉÄÜÓбØÒª²ÉÄÉAIÁÙ´²¾ö²ßÖ§³Ö£¨Clinical Decision Support, CDS£©¡£Èç¹ûAI¹¤¾ßµÄʹÓó¬³ö¼à¹ÜÊÚȨ£¨ÈçFDAÐí¿ÉºÍCE±êÖ¾£©Ö¸¶¨µÄÔ¤ÆÚÓÃ;£¬ÔðÈηçÏÕ»áÔö¼Ó£¬Òò´Ë´ÓÒµÕßÓ¦Á˽âÄ¿±êÈËȺºÍÊäÈëÊý¾ÝÒªÇóÒÔ±£³Ö·¨ÂÉÕýµ±ÐÔ¡£\n6 ÌÖÂÛ\n±¾×ÛÊöÇ¿µ÷ÁËAIºÍ»úÆ÷ѧϰ£¨ML£©ÔÚÉñ¾·ÅÉäѧÖеÄÑ¡¶¨½øÕ¹ºÍÁÙ´²Ç±Á¦£¬Ìرð¹Ø×¢¶àÖÐÐÄÑéÖ¤ºÍʵʩ¡£Ëù¿¼²ìµÄ¼Ü¹¹°üÀ¨cML¼°ÆäÑÜÉúDL¡ª¡ªÓÈÆäÊÇU-NetºÍnnU-NetµÈCNN¡ª¡ªÒÔ¼°¸üеÄTransformerºÍ»ù´¡Ä£ÐÍ¡£ÕâЩϵͳÔÚ¶àÖÖÉñ¾Ó°ÏñÓ¦ÓÃÖÐÕ¹ÏÖ³öÓÐÇ°¾°µÄÐÔÄÜ£¬´ÓÄÔÖ×ÁöºÍתÒÆÁö·Ö¸îµ½Ñª¹Ü²¡Àí¼ì²âºÍ¼ø±ðÕï¶ÏÉú³É¡£¶àÖÐÐÄÑéÖ¤Ñо¿ÈÕÒæÖ§³ÖAIÄ£ÐÍ¿çɨÃèÒÇ¡¢ÈËȺºÍÓ°ÏñÐÒéµÄ·º»¯ÐÔ£¬Í¹ÏÔÆäÎȽ¡ÁÙ´²×ª»¯µÄDZÁ¦¡£ÖµµÃ×¢ÒâµÄÊÇ£¬¾¡¹ÜAIÔÚÉñ¾·ÅÉäѧÖпìËÙÔö³¤£¬µ«Ïà¶Ô½ÏÉÙµÄÑо¿Äܳ¬Ô½µ¥ÖÐÐÄ¿ª·¢½øÈëÎȽ¡µÄ¶àÖÐÐÄÑéÖ¤£¬Õâ͹ÏÔÁË·½·¨´´ÐÂÓëÏÖʵÁÙ´²×ª»¯Ö®¼äµÄ¹Ø¼ü²î¾à¡£\n6.1 ¾ÖÏÞÐÔ\nÂ×ÀíÌôÕ½°üÀ¨¼¯ÖÐʽÊý¾ÝϵͳÖеĻ¼ÕßÒþ˽µ£ÓÇ¡¢Ëã·¨ºÍÊý¾Ý¼¯Æ«¼û£¬ÒÔ¼°GDPRºÍHIPAAµÈÊý¾Ý±£»¤¿ò¼ÜÖ´Ðв»Ò»Ö¡£¼¼ÊõºÍ·½·¨¾ÖÏÞÈÔÈ»´æÔÚ£ºµ±Ç°AIÄ£ÐÍÔÚѵÁ··½·¨¡¢Êý¾Ý¼¯×é³ÉºÍÑéÖ¤Ö¸±ê·½Ãæ±íÏÖ³öÒìÖÊÐÔ£»Ðí¶àϵͳȱ·¦¿É½âÊÍÐÔ£¬ºÜÉÙ¿¼ÂÇ»¼Õߺϲ¢Ö¢£¬ÇÒÔÚÓÐÏÞ»òÈË¿Úͳ¼ÆѧÏÁÕµÄÊý¾Ý¼¯ÉÏѵÁ·¡£È±·¦±ê×¼»¯»ù×¼ºÍ¿ÉÖظ´ÐÔÖ¸ÄϽøÒ»²½Ê¹ÁÙ´²ÆÀ¹À¸´ÔÓ»¯¡£±¾×ÛÊö±¾Éí´æÔÚÖØÒª¾ÖÏÞ£º×÷ΪÕë¶ÔÐÔ·¶Î§×ÛÊö£¬²¢·ÇÖ¼ÔÚÇ£¬ÄÉÈëÑо¿ÊýÁ¿Ïà¶Ô½ÏÉÙ·´Ó³ÁËÑϸñÄÉÈë±ê×¼¶Ô¶àÖÐÐÄÑéÖ¤µÄÌض¨¹Ø×¢£»¸÷Ñо¿¶Ô¡°¶àÖÐÐÄ¡±ÑéÖ¤¶¨ÒåµÄ¿É±äÐÔ¿ÉÄܵ¼ÖÂÒÅ©ʹÓöà»ú¹¹Êý¾Ýµ«Î´Ã÷È·ÃèÊöµÄÏà¹ØÎÄÏ×£»Ñо¿Éè¼Æ¡¢Êý¾Ý¼¯ºÍ±¨¸æÖ¸±êµÄÒìÖÊÐÔÏÞÖÆÑо¿¼äÖ±½Ó±È½Ï¡£\n6.2 ¿ÉÀ©Õ¹AIµÄ»ù´¡ÉèÊ©ÓëÕþ²ß\nAIÔÚÉñ¾Ó°ÏñÖеĿÉÀ©Õ¹²¿ÊðÐèÒªÎȽ¡µÄ»ù´¡ÉèÊ©ºÍά»¤¾«ÃܵÄÈíÓ²¼þ¡£ÔÚ»ù´¡²ãÃ棬ÕâЩϵͳÐèÒª±ê×¢Êý¾ÝÀ´²úÉú¹¦ÄÜÐÔѵÁ·Êý¾Ý¼¯£¬ÕâÐèÒªºÏ¸ñҽʦºÍר¼ÒµÄе÷Óë×Éѯ¡£ÔÚ»ú¹¹²ãÃ棬ҽԺ±ØÐëÈ·±£¾ß±¸ÔËÐÐÕâЩģÐ͵ݲȫ¼ÆËãÓ²¼þ£¬°üÀ¨´¦Àí¸ßÐÔÄܼÆËãÈÎÎñµÄ¼ÆËã»ú½ÚµãºÍͼÐδ¦Àíµ¥Ôª£¨Graphics Processing Units, GPUs£©¡£FL»¹ÐèÒªÖÐÑë¾ÛºÏ·þÎñÆ÷½øÐÐе÷ºÍÄ£Ð͸üС£ÕâЩÉ豸ÀíÏëÇé¿öÏÂÓ¦Å䱸Êʵ±µÄÈí¼þ£¬°üÀ¨Êý¾ÝÔ¤´¦Àí¹ÜµÀ¡¢ÐÅÏ¢°²È«µÄ¼ÓÃÜ·½·¨¡¢ÏµÍ³¼ä±£ÃÜÊý¾Ý½»»»µÄ°²È«²ÎÊýÐÒ顣ϵͳ±ØÐë¾ß±¸»¥²Ù×÷ÐÔ¡ª¡ª²»Í¬ÏµÍ³»òÉ豸ͨÐźͽ»»»Êý¾ÝµÄÄÜÁ¦¡ª¡ªÌرðÊÇ´ÓÓ°ÏñÉ豸´«ÊäÊý¾ÝºÍ¿çÖÐÐÄÁ¬½Ó¡£ÕâÇ¿µ÷ÁËʹÓÃҽѧÊý×Ö³ÉÏñºÍͨÐÅ£¨Digital Imaging and Communications in Medicine, DICOM£©±ê×¼½øÐд洢ºÍ½»»»ÐÒéÒÔ¼°Î¬³Ö±ê×¼»¯±ê×¢¿ò¼Ü½øÐÐÊý¾Ý±ê×¢µÄÖØÒªÐÔ¡£Ó²¼þÒìÖÊÐÔÒ²ÒýÈëÁË´àÈõÐÔ£¬Ôì³ÉѵÁ·²î¾àºÍ´ú±íÐÔ²»×㣬Òò´Ë¿çÓ°Ïñģ̬µÄÊý¾Ýе÷£¨ÈçMRIÊý¾Ý¼¯µÄÏñËØÇ¿¶È¹éÒ»»¯¼¼Êõ£©¾ßÓмÛÖµ¡£Õþ²ß¿ò¼ÜͬÑù¹Ø¼ü£¬ÓÃÓÚʵʩ¿ÉÀ©Õ¹Êý¾Ý¼¯µÄÖÎÀí¡¢×ñÊØÒþ˽Á¢·¨ºÍ×ÊÖú¼¼Êõ»ù´¡ÉèÊ©¡£\n6.3 δÀ´¿¼Á¿\nδÀ´Ñо¿Ó¦¾Û½¹¶àģ̬ÕûºÏ£¬½«¶àÖÖÓ°Ïñģ̬£¨ÈçMRI¡¢CT¡¢PET£©ÓëÁÙ´²ºÍÒÅ´«Êý¾Ý½áºÏ£¬ÒÔÌá¸ßÕï¶Ï׼ȷÐÔºÍÇé¾³Àí½â¡£ADNIµÈ¿ª·Å»ñÈ¡Êý¾Ý¼¯Ó¦À©Õ¹ÒÔ½â¾öÊý¾ÝÒìÖÊÐÔ²¢Í¨¹ýÈ«Çò´ú±íÐÔ´Ù½øËã·¨¹«Æ½ÐÔ¡£ÎªÆ½ºâÒþ˽ÓëÐÔÄÜ£¬Áª°îѧϰ£¨FL£©ºÍÎ޼ලÓòÊÊÓ¦£¨Unsupervised Domain Adaptation, UDA£©ÒÑ»ñµÃ¹Ø×¢¡£FLʵÏÖÎÞÐè¹²ÏíÔʼÊý¾ÝµÄÈ¥ÖÐÐÄ»¯Ä£ÐÍѵÁ·£¬¶øUDAÔÊÐíÄ£ÐÍͨ¹ýÀûÓÃÏÈǰѧϰ·º»¯µ½Î´±ê×¢»òÓòÆ«ÒƵÄÊý¾Ý¼¯¡£UDA¿É»º½â¡°ÓòÆ«ÒÆ¡±ÎÊÌ⣬ʹģÐÍÊÊÓ¦ºÍÓÅ»¯µ½¶à¸ö²»Í¬Êý¾ÝÔ´ºÍÓò£¬Ãֺϱê×¢ÄÚ²¿Ô´ÓëÐÂÍⲿ¶ÓÁÐÖ®¼äµÄ²î¾à¡£È»¶ø£¬È¥ÖÐÐÄ»¯¿ÉÄÜ·Å´óÊý¾Ý¼¯±äÒìÐÔ²¢Ê¹ÖÊÁ¿¿ØÖƸ´ÔÓ»¯¡£»¹Ó¦¿¼ÂDZê×¼»¯³ÉÏñÐÒéÒÔÔÚÊäÈë²ãÃæ½â¾ö²»Ò»ÖÂÐÔ¡£ÁíÒ»ÖÖ·½·¨¡ª¡ªÊ¹ÓÃÄäÃû»¯¶à»ú¹¹Êý¾Ý½øÐа²È«¼¯ÖÐѵÁ·¡ª¡ª¿ÉÔÚͨ¹ý±ê×¼»¯Ô¤´¦ÀíºÍÖÊÁ¿±£Ö¤¸ÄÉÆÒ»ÖÂÐÔµÄͬʱ±£³ÖÒþ˽¡£½üÆÚ»¹Ìá³öÁË¡°Áª°îÓòÊÊÓ¦¡±£¬¼´ÑµÁ·Ò»¸öͨÓÃÄ£ÐͲ¢¸¨ÒÔ¸üרҵ»¯µÄÓòµ÷ÓÅ˽ÓÐÄ£ÐÍ£¬ËüÃÇÏ໥½»»¥ÒÔ´ï³É¹²Í¬Êä³ö¡£AIÔÚÉñ¾·ÅÉäѧÖеĸºÔðÈÎÍƽø»¹ÐèÒª¸üÇ¿ÓÐÁ¦µÄ¼à¹ÜºÍÔËÓª¿ò¼Ü¡£HIPAAºÍGDPRµÈÏÖÐз¨ÂÉÌṩÁË»ù´¡Ö¸µ¼£¬µ«Î´Õë¶ÔAIÌØÓÐÌôÕ½½øÐж¨ÖÆ£¬ÌرðÊÇÄ£ÐÍÖØѵÁ·¡¢¿É½âÊÍÐÔºÍÊý¾ÝËÝÔ´¡£ÕâЩ¼à¹Ü·¾¶Í¨³£ÓÅÏÈ¿¼ÂǾ²Ì¬ÑéÖ¤£º²¿ÊðÇ°¶Ô¹Ì¶¨Ä£ÐͽøÐе¥´ÎÆÀ¹À£¬¶øδ¿¼ÂDz¿Êðºó¸üпÉÄܵ¼ÖµÄÐÔÄܱ仯¡£ÕâÒ»¾ÖÏÞ¶Ô²¿Êðºó³ÖÐøѧϰµÄ×ÔÊÊӦģÐÍÓÈΪÖØÒª£¬ÒòΪ³ÖÐø¸üпÉÄÜÎÞ·¨ÔÚ²»Öظ´ÉóÅúÁ÷³ÌµÄÇé¿öÏÂÇáÒ×±»ÈÝÄÉ¡£ÐèÒª¹ú¼ÊºÏ×÷À´Öƶ¨ÃæÏòAIµÄÊý¾ÝÖÎÀíÖ¸ÄϺÍÂ×Àí±ê×¼£¬È·±£»¼Õß°²È«ºÍ»¥²Ù×÷ÐÔ¡£´ËÍ⣬¾¼Ã·ÖÎö¡ª¡ª°üÀ¨Ä£ÐÍѵÁ·¡¢»ù´¡ÉèÊ©ºÍÁÙ´²ÕûºÏ³É±¾¡ª¡ªÓ¦ÎªÕþ²ßºÍ²ÉÄɲßÂÔÌṩÐÅÏ¢¡£×ÝÏò¶àÖÐÐÄÑо¿ÆÀ¹Àʱ¼äЧÂÊ¡¢¿ÉÀ©Õ¹ÐԺͳ¤ÆÚ»¼Õß½á¾Ö¶ÔÓÚÔÚÏÖʵ»·¾³ÖÐÑéÖ¤ÕâЩ¹¤¾ßÖÁ¹ØÖØÒª¡£Ëæ×ÅÁÙ´²Ò½Ê¦¶ÔAIÊìϤ¶ÈµÄÌá¸ß£¬Åàѵ¼Æ»®ºÍ»ú¹¹Ö§³Ö½«È·±£×¼È·½â¶Á²¢¼õÉÙÎóÓá£ËæןßÐÔÄÜAIÄ£ÐÍÈÕÒæÈÚÈëÁÙ´²¹¤×÷Á÷³Ì£¬·ÅÉä¿ÆҽʦµÄ½ÇÉ«¿ÉÄÜ´ÓÖ÷ҪͼÏñ½â¶ÁÕßת±äΪ¸ü¾ß¼à¶½ÐÔµÄλÖ㬳䵱Ëã·¨Êä³öµÄÑéÖ¤Õß¡£\n7 ½áÂÛ\nAIÒѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧµÄ¸ñ¾Ö£¬ÔÚÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌЧÂʺÍÁÙ´²¾ö²ßÖ§³Ö£¨CDS£©·½ÃæÌṩÁËÇ°ËùδÓеĽøÕ¹¡£CNN¡¢U-Net±äÌåºÍÐÂÐË»ù´¡Ä£Ð͵ÈDL¼Ü¹¹ÔÚ¶àÖÖÓ°ÏñÈÎÎñÖÐÕ¹ÏÖ³ö׿ԽÐÔÄÜ£¬°üÀ¨²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºó·ÖÎö¡£È»¶ø£¬°éËæÕâЩ¼¼ÊõÊÕÒæ¶øÀ´µÄÊǸ´ÔÓµÄÂ×Àí¡¢¼à¹ÜºÍʵ¼ùÌôÕ½¡£Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼û¡¢¿É½âÊÍÐԺͲ»¹«Æ½»ñÈ¡µÈÎÊÌâ±ØÐëÔڹ㷺ÁÙ´²ÕûºÏ֮ǰµÃµ½½â¾ö¡£ÎȽ¡µÄÖÎÀí¿ò¼Ü¡¢Í¸Ã÷µÄÑéÖ¤ºÍ°üÈÝÐÔµÄÊý¾Ý¼¯´ú±íÐÔ¶ÔÓÚÈ·±£AIϵͳ°²È«¹«Æ½µØ·þÎñ»¼ÕßÖÁ¹ØÖØÒª¡£ÁÙ´²Ò½Ê¦¡¢Ñо¿ÈËÔ±¡¢¹¤³ÌʦºÍÕþ²ßÖƶ¨ÕßÖ®¼äµÄ³ÖÐøÐ×÷¶ÔÓÚÃֺϴ´ÐÂÓ븺ÔðÈÎʵʩ֮¼äµÄ²î¾àÖÁ¹ØÖØÒª¡£Ëæ×ÅÁìÓò³ÉÊ죬ÖصãÓ¦´Ó¸ÅÄîÑé֤׼ȷÐÔתÏò¿É½âÊÍÐÔ¡¢·º»¯ÐÔºÍÂ×Àí¹ÜÀí¡£Í¨¹ý³ÖÐøµÄ¿çѧ¿ÆºÏ×÷ºÍ¼à¶½£¬AIÔÚÉñ¾Ó°ÏñѧÖв»½öÓÐÍûÌá¸ßÕï¶Ï¾«¶È£¬»¹ÓÐÍûÒÔ¹«Æ½¿ÉÐŵķ½Ê½ÖØж¨ÒåÉñ¾»¤Àí±ê×¼¡£","image_url":null,"lang":"zh","published_at":"2026-09-27T01:00:54+00:00","fetched_at":"2026-09-27T01:15:07+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs.","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 14247 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":14247,"summary_length":5898,"usable_text_length":14247,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":14247,"summary_length":5898}},"news_item":{"id":90989,"canonical_url":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","source_url":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","title":"人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量 - 生物通","source_name":"生物通","author":null,"published_at":"2026-09-27T01:00:54+00:00","locale":"zh","topic":"ai","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMibEFVX3lxTE1tZVVBc0N3U0pPR01Oc1pXU25mVnM3c2hLdkRFMUU4TEtiVVNfTmU4aHFTelZneVRuY1FVRkxWakIyWi04N01CZGtaUlVJNkFLRERfVExQdXJLbndFS01UTDJzdGVuUVFZWUFCdw?oc=5\" target=\"_blank\">人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">生物通</font>","full_text":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ·ÅÉä¿Æҽʦ33.3%£©£¬×÷Ϊ¸¨Öú¹¤¾ßʱÁéÃô¶ÈÏÔÖøÌá¸ß£¨Ê¹ÓÃAI 41.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs. 135, p<0.001£©¡£RauscheckerµÈÈËÆÀ¹ÀÁ˽áºÏDLºÍ±´Ò¶Ë¹ÍøÂçµÄMRI¼ø±ðÕï¶ÏAIϵͳ£¬Ëã·¨´ïµ½91%µÄÇ°ÈýλÕï¶Ï׼ȷÂÊ£¬±íÏÖÓëѧÊõÉñ¾·ÅÉä¿ÆҽʦÏ൱£¨86%; p=0.20£©£¬ÓÅÓÚסԺҽʦ£¨56%; p<0.001£©¡¢½øÐÞҽʦ£¨77%; p=0.003£©ºÍÆÕͨ·ÅÉä¿Æҽʦ£¨57%; p<0.001£©¡£\n4.2 ÁÙ´²ÊµÊ©Ó빤×÷Á÷³ÌÓ°Ïì\nÔÚ¼±ÐÔÉñ¾Ó°ÏñѧÖУ¬»ùÓÚCNNµÄÄ£ÐÍÔÚ´óѪ¹Ü±ÕÈû£¨Large Vessel Occlusion, LVO£©×äÖмì²âÖдﵽ85%µÄÁéÃô¶È£¬ÏÔÖøÓÅÓÚËæ»úÉÁÖÄ£ÐÍ£¨68%£©£¬²¢¾ßÓмÓËÙ·ÖÕïºÍÖÎÁÆʱ¼äÏßµÄDZÁ¦¡£RAPID ICH¡¢Viz.aiºÍAldoc MedicalµÈ¹¤¾ßÀûÓÃDL×Ô¶¯Ê¶±ðºÍ·ÖÀàCTÉϵijöѪ£¬×÷ΪʵʱÕï¶Ï¸¨Öú£¬Ìṩ¡°¶þ´ÎÔĶÁ¡±¡¢ÐÖúÖÊÁ¿±£Ö¤²¢°ïÖú·ÅÉä¿ÆҽʦÓÅÏÈ´¦Àí½ô¼±²¡Àý£¬¿ÉÄܼõÉÙÅжÁÑÓ³Ù¡£\n4.3 ÕæʵÊÀ½ç²ÉÓÃÓëÓû§ÈÏÖª\nº«¹ú·ÅÉä¿Æҽʦȫ¹úµ÷²éÏÔʾ£¬60.3%£¨223/370£©Òѽ«»ùÓÚAIµÄÈí¼þÄÉÈëʵ¼ù£¬Ö÷ÒªÓÃÓÚ²¡Ôî¼ì²â£¨82.1%£©¡¢Õï¶Ï¸¨Öú£¨55.2%£©ºÍͼÏñ·ÖÀࣨ55.2%£©¡£67.6%µÄÊÜ·ÃÕß×¢Òâµ½»¼Õß¹ÜÀíµÄ¸ÄÉÆ£¬85.1%¶ÔAIÐÔÄܱíʾ×ÜÌåÂúÒ⡣Ȼ¶ø£¬92%µÄÊÜ·ÃÕßÈÏΪÐèÒªÕý¹æ½ÌÓýºÍÖ¸ÄÏÒÔÈ·±£AIÊä³öµÄÊʵ±Ê¹Óúͽâ¶Á¡£\n4.4 ÁÙ´²½á¾Ö×ܽá\nÔÚ¶à¸öÁìÓò£¬AIÇý¶¯µÄÉñ¾Ó°ÏñϵͳչÏÖ³ö¸ßÕï¶Ï׼ȷÐÔ¡¢Ð§ÂʺͿÉÀ©Õ¹ÐÔ£¬ÐÔÄܳ£Óëר¼ÒÉñ¾·ÅÉä¿ÆҽʦÏ൱¡£ÆäÁÙ´²ÕûºÏÌṩÁ˼ò»¯¹¤×÷Á÷³Ì¡¢Ö§³Ö¾ö²ßºÍ¸ÄÉÆ»¼Õß½á¾ÖµÄ»ú»á¡£È»¶ø£¬ÕâЩÒæ´¦ÒÀÀµÓÚÑϸñµÄ¶àÖÐÐÄÑéÖ¤ÒÔ¼°¶Ô¿É½âÊÍÐÔ¡¢ÁÙ´²Ò½Ê¦½ÌÓýºÍÂ×ÀíÖÎÀíµÄ³ÖÐø¹Ø×¢¡£\n5 Â×Àí¿¼Á¿Óë¾ÖÏÞÐÔ\n5.1 Êý¾ÝÒþ˽ÓëÖÎÀí\nÊý¾ÝÒþ˽ÊÇAIÇý¶¯Éñ¾Ó°ÏñÖÐ×î½ôÆȵÄÂ×Àí¹ØÇÐÖ®Ò»£¬ÓÈÆäÊǵ±´óÐÍÓ°ÏñÊý¾Ý¼¯´æ´¢ÔÚ¿ç¹ú¼Ê±ß½ç¾ÛºÏÐÅÏ¢µÄÃÅ»§»òÔÆϵͳÖÐʱ¡£ÄÔ²¿É¨Ãè¾ßÓжÀÌØ·çÏÕ£¬ÒòΪ½âÆʽṹ¿ÉÓë¸öÈËÊý¾ÝÆ¥Åä´Ó¶øʵÏÖÔÙʶ±ð¡£Å·ÃËͨÓÃÊý¾Ý±£»¤ÌõÀý£¨GDPR£©Çø·Ö¸öÈËÊý¾Ý¡¢È¥±êʶ»¯Êý¾ÝºÍÍêÈ«ÄäÃûÊý¾Ý£¬¶øÖйú¸öÈËÐÅÏ¢±£»¤·¨£¨PIPL£©½«ÉúÎïʶ±ðºÍÒ½ÁÆÐÅÏ¢¹éÀàΪ¸ß¶ÈÃô¸ÐÊý¾Ý¡£È»¶ø£¬¹ú¼ÒºÍ»ú¹¹¼äÒþ˽·¨ÂɵÄÒìÖÊÐÔʹ¿ç¾³Êý¾Ý¹²Ïí¸´ÔÓ»¯¡£Áª°îѧϰ£¨FL£©Äܹ»ÔÚÎÞÐè´«ÊäÔʼÊý¾ÝµÄÇé¿öϽøÐпç»ú¹¹Ä£ÐÍѵÁ·£¬¼õÉÙ¼¯Öд洢¿âµÄÐèÇó¡£Êý¾ÝʹÓÃÐÒ飨Data Use Agreements, DUAs£©ºÍÊý¾Ý´«ÊäÐÒ飨Data Transfer Agreements, DTAs£©µÈÕýʽÐÒ鶨ÒåÁËÔðÈβ¢·ÀÖ¹ÀÄÓá£\n5.2 żȻ·¢ÏÖÓë¿É½âÊÍÐÔ\nżȻ·¢ÏֵĹÜÀí¡ª¡ªÑо¿»òÕï¶ÏÓ°ÏñÖз¢ÏÖµÄÒâÍâÒì³£¡ª¡ªÌá³öÁËÁíÒ»Â×ÀíÀ§¾³¡£AIϵͳÒò¸ßÁéÃô¶ÈºÍÐí¶àDLÄ£Ð͵ġ°ºÚÏ䡱ÌØÐÔ¶ø¼Ó¾çÁËÕâÒ»ÎÊÌ⣬ÏÞÖÆÁËÁÙ´²Ò½Ê¦½â¶ÁËã·¨ÍÆÀíµÄÄÜÁ¦¡£AIϵͳµÄ¿ª·¢ÕßÓ¦·ÅÆúÓÅÏÈ¿¼ÂÇÉÌÒµÃØÃܶø·Ç͸Ã÷ÐԵġ°ÒþÐοÆѧ¡±×ö·¨¡£¿ª·¢Õß±ØÐëÈ·±£³ÖÐø¼à²âºÍƵ·±ÓÅ»¯AIϵͳ£¬ÒÔ¸úÉϲ»¶Ï·¢Õ¹µÄÁÙ´²Êµ¼ù¡£ÁÙ´²Ò½Ê¦ÔÚ½«ÕâЩ¹¤¾ßÕûºÏµ½ÁÙ´²Êµ¼ùÖÐʱÐèÒª²Éȡƽºâ·½·¨£¬Í¬Ê±²»Ëðº¦ÆäÁÙ´²Åжϡ£½«Î±Ó°»òÕý³£±äÒìÎóʶ±ðΪ²¡Àí¿Éµ¼Ö»¼Õß½¹ÂÇ¡¢²»±ØÒªµÄËæ·Ã¼ì²é»òÎóÕï¡£¸÷˾·¨¹ÜϽÇø¼à¹Ü¿ò¼ÜµÄ²»Ò»ÖÂÐÔʹµÃ½¨Á¢±ê×¼»¯³ÌÐòÀ´¹ÜÀíÕâЩ·¢ÏÖ±äµÃÀ§ÄÑ¡£\n5.3 Ë㷨ƫ¼ûÓ빫ƽÐÔ\nË㷨ƫ¼ûÊÇAIÔÚÉñ¾Ó°ÏñÖÐÂ×ÀíÓ¦Óõĸù±¾¾ÖÏÞ¡£Ò»Ïî½üÆÚÜöÝÍ·ÖÎö·¢ÏÖ£¬97.5%µÄѵÁ·Êý¾Ý¼¯À´×Ô¸ßÊÕÈë»òÖиßÊÕÈëµØÇø£¬µ¼ÖÂϵͳÐÔȱ·¦¶àÑùÐÔ£¬Ï÷ÈõÁËÈ«ÇòÊÊÓÃÐÔ¡£Ò»ÏîAIÕï¶Ï°¢¶û´Äº£Ä¬²¡µÄÑо¿ËµÃ÷ÁËÕâһЧӦ£ºÔÚÃÀ¹ú°¢¶û´Äº£Ä¬²¡Éñ¾Ó°Ïñѧ³«Ò飨Alzheimer's Disease Neuroimaging Initiative, ADNI£©Êý¾Ý¼¯ÉÏѵÁ·µÄCNNÔÚ°Ä´óÀûÑÇAIBL¶ÓÁÐÖбíÏÖÁ¼ºÃ£¬µ«ÔÚÒâ´óÀûI-ADNIÊý¾Ý¼¯ÉÏÏÔÖø¶ñ»¯£¬×¼È·ÂʽöΪ78%¡£Ðí¶àÓÃÓÚAI¿ª·¢µÄ»ùÓÚ»úÆ÷ѧϰ£¨Machine Learning, ML£©µÄÊý¾Ý¿âÀ´×Ô¸ßÊÕÈë¹ú¼Ò£¨Å·Ö޺ͱ±ÃÀ£©£¬¶ÔÑÇÖÞ¡¢À¶¡ÃÀÖ޺ͷÇÖÞÈËȺµÄÄÉÈëÓÐÏÞ£¬Ôì³É¡°Ã÷È·µÄselection bias¡±¡£Ó¦Öƶ¨Õþ²ßÇ¿ÖÆÄÉÈëÖÖ×å¡¢Ãñ×å¡¢ÄêÁä¡¢ÐÔ±ðºÍÉç»á¾¼ÃµØλµÈÈË¿Úͳ¼Æѧ±äÁ¿ÒÔ½øÐÐÆ«¼ûÉó¼Æ¡£Ó¦²ÉÓÃFUTURE-AIÖ¸ÄϵÈÂ×Àí×¼Ôò£¬È·±£¹«Æ½ÐÔºÍÆÕ±éÐÔÔÔòÈÚÈ뿪·¢¹ý³Ì¡£ÃÀ¹ú¡°All of Us¡±Ñо¿¼Æ»®µÈ¿É×÷Ϊ³¬Ô½µØÀíºÍÉç»á¾¼Ã±ß½ç´´½¨È«ÇòÊý¾Ý¿âµÄÄ£ÐÍ¡£\n5.4 ¼à¹ÜÓëʵ¼ù¾ÖÏÞÐÔ\nÏÖÐмà¹Ü»·¾³ÉÐδÊÊÓ¦¶àÖÐÐÄAIÑо¿µÄ¸´ÔÓÐÔ¡£¹ÜÀíÁÙ´²Êý¾Ý¼¯ÊÕ¼¯¡¢Ê¹Óúͽ»»»µÄÉç»á·¨ÂÉ¿ò¼Ü²îÒì×è°Á˹ú¼ÊºÏ×÷¡£´ËÍ⣬Õë¶Ô³ÖÐø´ÓÐÂÊý¾ÝѧϰµÄ×ÔÊÊÓ¦Ëã·¨µÄÉÏÊкó¼à²â»òÑéÖ¤±ê×¼»¯³ÌÐòºÜÉÙ¡£È±·¦È«Ãæ¼à¶½Ê±£¬Â×ÀíºÍ°²È«Ê§Îó¿ÉÄÜÔÚ»¼ÕßÉ˺¦·¢ÉúÇ°²»±»·¢ÏÖ¡£\n5.5 ·¨ÂÉÔðÈÎ\nAI¸¨ÖúÉñ¾Ó°ÏñµÄÁíÒ»¸ö¹ØÇÐÊÇ·¨ÂÉÔðÈΣ¬ÒòΪҽʦ³Ðµ£Õï¶ÏÔðÈΡ£ÔðÈα»ÊÓΪÁÙ´²Ò½Ê¦ÓëË㷨ϵͳ֮¼äµÄ·Ö²¼Ê½¹¹½¨£¬·´Ó³ÁËÁÙ´²Êµ¼ùÖÐÏò¹²Ïí¾ö²ß·¶Ê½µÄת±ä¡£Îª½µµÍ·¨ÂÉ·çÏÕ£¬ÁÙ´²Ò½Ê¦±ØÐëÈ·±£AIµÄʹÓ÷ûºÏͬһר¿ÆºÏ¸ñ´ÓÒµÕߵıê×¼»¤Àíˮƽ¡£·¨ÂÉ·ÖÎö¿¼ÂÇÁ½ÖÖÇéÐΣºÒ»ÊÇҽʦ¾Ü¾øÁË·ûºÏ±ê×¼»¤ÀíµÄÕýÈ·½¨Ò飻¶þÊÇҽʦ×ñÑÁ˲»·ûºÏ±ê×¼»¤ÀíµÄ´íÎóAI½¨Òé¡£Èç¹ûAIÄܳ¬Ô½ÈËÀà¾ö²ßÄÜÁ¦£¬·¨ÂÉר¼ÒÔ¤²â¿ÉÄÜÓбØÒª²ÉÄÉAIÁÙ´²¾ö²ßÖ§³Ö£¨Clinical Decision Support, CDS£©¡£Èç¹ûAI¹¤¾ßµÄʹÓó¬³ö¼à¹ÜÊÚȨ£¨ÈçFDAÐí¿ÉºÍCE±êÖ¾£©Ö¸¶¨µÄÔ¤ÆÚÓÃ;£¬ÔðÈηçÏÕ»áÔö¼Ó£¬Òò´Ë´ÓÒµÕßÓ¦Á˽âÄ¿±êÈËȺºÍÊäÈëÊý¾ÝÒªÇóÒÔ±£³Ö·¨ÂÉÕýµ±ÐÔ¡£\n6 ÌÖÂÛ\n±¾×ÛÊöÇ¿µ÷ÁËAIºÍ»úÆ÷ѧϰ£¨ML£©ÔÚÉñ¾·ÅÉäѧÖеÄÑ¡¶¨½øÕ¹ºÍÁÙ´²Ç±Á¦£¬Ìرð¹Ø×¢¶àÖÐÐÄÑéÖ¤ºÍʵʩ¡£Ëù¿¼²ìµÄ¼Ü¹¹°üÀ¨cML¼°ÆäÑÜÉúDL¡ª¡ªÓÈÆäÊÇU-NetºÍnnU-NetµÈCNN¡ª¡ªÒÔ¼°¸üеÄTransformerºÍ»ù´¡Ä£ÐÍ¡£ÕâЩϵͳÔÚ¶àÖÖÉñ¾Ó°ÏñÓ¦ÓÃÖÐÕ¹ÏÖ³öÓÐÇ°¾°µÄÐÔÄÜ£¬´ÓÄÔÖ×ÁöºÍתÒÆÁö·Ö¸îµ½Ñª¹Ü²¡Àí¼ì²âºÍ¼ø±ðÕï¶ÏÉú³É¡£¶àÖÐÐÄÑéÖ¤Ñо¿ÈÕÒæÖ§³ÖAIÄ£ÐÍ¿çɨÃèÒÇ¡¢ÈËȺºÍÓ°ÏñÐÒéµÄ·º»¯ÐÔ£¬Í¹ÏÔÆäÎȽ¡ÁÙ´²×ª»¯µÄDZÁ¦¡£ÖµµÃ×¢ÒâµÄÊÇ£¬¾¡¹ÜAIÔÚÉñ¾·ÅÉäѧÖпìËÙÔö³¤£¬µ«Ïà¶Ô½ÏÉÙµÄÑо¿Äܳ¬Ô½µ¥ÖÐÐÄ¿ª·¢½øÈëÎȽ¡µÄ¶àÖÐÐÄÑéÖ¤£¬Õâ͹ÏÔÁË·½·¨´´ÐÂÓëÏÖʵÁÙ´²×ª»¯Ö®¼äµÄ¹Ø¼ü²î¾à¡£\n6.1 ¾ÖÏÞÐÔ\nÂ×ÀíÌôÕ½°üÀ¨¼¯ÖÐʽÊý¾ÝϵͳÖеĻ¼ÕßÒþ˽µ£ÓÇ¡¢Ëã·¨ºÍÊý¾Ý¼¯Æ«¼û£¬ÒÔ¼°GDPRºÍHIPAAµÈÊý¾Ý±£»¤¿ò¼ÜÖ´Ðв»Ò»Ö¡£¼¼ÊõºÍ·½·¨¾ÖÏÞÈÔÈ»´æÔÚ£ºµ±Ç°AIÄ£ÐÍÔÚѵÁ··½·¨¡¢Êý¾Ý¼¯×é³ÉºÍÑéÖ¤Ö¸±ê·½Ãæ±íÏÖ³öÒìÖÊÐÔ£»Ðí¶àϵͳȱ·¦¿É½âÊÍÐÔ£¬ºÜÉÙ¿¼ÂÇ»¼Õߺϲ¢Ö¢£¬ÇÒÔÚÓÐÏÞ»òÈË¿Úͳ¼ÆѧÏÁÕµÄÊý¾Ý¼¯ÉÏѵÁ·¡£È±·¦±ê×¼»¯»ù×¼ºÍ¿ÉÖظ´ÐÔÖ¸ÄϽøÒ»²½Ê¹ÁÙ´²ÆÀ¹À¸´ÔÓ»¯¡£±¾×ÛÊö±¾Éí´æÔÚÖØÒª¾ÖÏÞ£º×÷ΪÕë¶ÔÐÔ·¶Î§×ÛÊö£¬²¢·ÇÖ¼ÔÚÇ£¬ÄÉÈëÑо¿ÊýÁ¿Ïà¶Ô½ÏÉÙ·´Ó³ÁËÑϸñÄÉÈë±ê×¼¶Ô¶àÖÐÐÄÑéÖ¤µÄÌض¨¹Ø×¢£»¸÷Ñо¿¶Ô¡°¶àÖÐÐÄ¡±ÑéÖ¤¶¨ÒåµÄ¿É±äÐÔ¿ÉÄܵ¼ÖÂÒÅ©ʹÓöà»ú¹¹Êý¾Ýµ«Î´Ã÷È·ÃèÊöµÄÏà¹ØÎÄÏ×£»Ñо¿Éè¼Æ¡¢Êý¾Ý¼¯ºÍ±¨¸æÖ¸±êµÄÒìÖÊÐÔÏÞÖÆÑо¿¼äÖ±½Ó±È½Ï¡£\n6.2 ¿ÉÀ©Õ¹AIµÄ»ù´¡ÉèÊ©ÓëÕþ²ß\nAIÔÚÉñ¾Ó°ÏñÖеĿÉÀ©Õ¹²¿ÊðÐèÒªÎȽ¡µÄ»ù´¡ÉèÊ©ºÍά»¤¾«ÃܵÄÈíÓ²¼þ¡£ÔÚ»ù´¡²ãÃ棬ÕâЩϵͳÐèÒª±ê×¢Êý¾ÝÀ´²úÉú¹¦ÄÜÐÔѵÁ·Êý¾Ý¼¯£¬ÕâÐèÒªºÏ¸ñҽʦºÍר¼ÒµÄе÷Óë×Éѯ¡£ÔÚ»ú¹¹²ãÃ棬ҽԺ±ØÐëÈ·±£¾ß±¸ÔËÐÐÕâЩģÐ͵ݲȫ¼ÆËãÓ²¼þ£¬°üÀ¨´¦Àí¸ßÐÔÄܼÆËãÈÎÎñµÄ¼ÆËã»ú½ÚµãºÍͼÐδ¦Àíµ¥Ôª£¨Graphics Processing Units, GPUs£©¡£FL»¹ÐèÒªÖÐÑë¾ÛºÏ·þÎñÆ÷½øÐÐе÷ºÍÄ£Ð͸üС£ÕâЩÉ豸ÀíÏëÇé¿öÏÂÓ¦Å䱸Êʵ±µÄÈí¼þ£¬°üÀ¨Êý¾ÝÔ¤´¦Àí¹ÜµÀ¡¢ÐÅÏ¢°²È«µÄ¼ÓÃÜ·½·¨¡¢ÏµÍ³¼ä±£ÃÜÊý¾Ý½»»»µÄ°²È«²ÎÊýÐÒ顣ϵͳ±ØÐë¾ß±¸»¥²Ù×÷ÐÔ¡ª¡ª²»Í¬ÏµÍ³»òÉ豸ͨÐźͽ»»»Êý¾ÝµÄÄÜÁ¦¡ª¡ªÌرðÊÇ´ÓÓ°ÏñÉ豸´«ÊäÊý¾ÝºÍ¿çÖÐÐÄÁ¬½Ó¡£ÕâÇ¿µ÷ÁËʹÓÃҽѧÊý×Ö³ÉÏñºÍͨÐÅ£¨Digital Imaging and Communications in Medicine, DICOM£©±ê×¼½øÐд洢ºÍ½»»»ÐÒéÒÔ¼°Î¬³Ö±ê×¼»¯±ê×¢¿ò¼Ü½øÐÐÊý¾Ý±ê×¢µÄÖØÒªÐÔ¡£Ó²¼þÒìÖÊÐÔÒ²ÒýÈëÁË´àÈõÐÔ£¬Ôì³ÉѵÁ·²î¾àºÍ´ú±íÐÔ²»×㣬Òò´Ë¿çÓ°Ïñģ̬µÄÊý¾Ýе÷£¨ÈçMRIÊý¾Ý¼¯µÄÏñËØÇ¿¶È¹éÒ»»¯¼¼Êõ£©¾ßÓмÛÖµ¡£Õþ²ß¿ò¼ÜͬÑù¹Ø¼ü£¬ÓÃÓÚʵʩ¿ÉÀ©Õ¹Êý¾Ý¼¯µÄÖÎÀí¡¢×ñÊØÒþ˽Á¢·¨ºÍ×ÊÖú¼¼Êõ»ù´¡ÉèÊ©¡£\n6.3 δÀ´¿¼Á¿\nδÀ´Ñо¿Ó¦¾Û½¹¶àģ̬ÕûºÏ£¬½«¶àÖÖÓ°Ïñģ̬£¨ÈçMRI¡¢CT¡¢PET£©ÓëÁÙ´²ºÍÒÅ´«Êý¾Ý½áºÏ£¬ÒÔÌá¸ßÕï¶Ï׼ȷÐÔºÍÇé¾³Àí½â¡£ADNIµÈ¿ª·Å»ñÈ¡Êý¾Ý¼¯Ó¦À©Õ¹ÒÔ½â¾öÊý¾ÝÒìÖÊÐÔ²¢Í¨¹ýÈ«Çò´ú±íÐÔ´Ù½øËã·¨¹«Æ½ÐÔ¡£ÎªÆ½ºâÒþ˽ÓëÐÔÄÜ£¬Áª°îѧϰ£¨FL£©ºÍÎ޼ලÓòÊÊÓ¦£¨Unsupervised Domain Adaptation, UDA£©ÒÑ»ñµÃ¹Ø×¢¡£FLʵÏÖÎÞÐè¹²ÏíÔʼÊý¾ÝµÄÈ¥ÖÐÐÄ»¯Ä£ÐÍѵÁ·£¬¶øUDAÔÊÐíÄ£ÐÍͨ¹ýÀûÓÃÏÈǰѧϰ·º»¯µ½Î´±ê×¢»òÓòÆ«ÒƵÄÊý¾Ý¼¯¡£UDA¿É»º½â¡°ÓòÆ«ÒÆ¡±ÎÊÌ⣬ʹģÐÍÊÊÓ¦ºÍÓÅ»¯µ½¶à¸ö²»Í¬Êý¾ÝÔ´ºÍÓò£¬Ãֺϱê×¢ÄÚ²¿Ô´ÓëÐÂÍⲿ¶ÓÁÐÖ®¼äµÄ²î¾à¡£È»¶ø£¬È¥ÖÐÐÄ»¯¿ÉÄÜ·Å´óÊý¾Ý¼¯±äÒìÐÔ²¢Ê¹ÖÊÁ¿¿ØÖƸ´ÔÓ»¯¡£»¹Ó¦¿¼ÂDZê×¼»¯³ÉÏñÐÒéÒÔÔÚÊäÈë²ãÃæ½â¾ö²»Ò»ÖÂÐÔ¡£ÁíÒ»ÖÖ·½·¨¡ª¡ªÊ¹ÓÃÄäÃû»¯¶à»ú¹¹Êý¾Ý½øÐа²È«¼¯ÖÐѵÁ·¡ª¡ª¿ÉÔÚͨ¹ý±ê×¼»¯Ô¤´¦ÀíºÍÖÊÁ¿±£Ö¤¸ÄÉÆÒ»ÖÂÐÔµÄͬʱ±£³ÖÒþ˽¡£½üÆÚ»¹Ìá³öÁË¡°Áª°îÓòÊÊÓ¦¡±£¬¼´ÑµÁ·Ò»¸öͨÓÃÄ£ÐͲ¢¸¨ÒÔ¸üרҵ»¯µÄÓòµ÷ÓÅ˽ÓÐÄ£ÐÍ£¬ËüÃÇÏ໥½»»¥ÒÔ´ï³É¹²Í¬Êä³ö¡£AIÔÚÉñ¾·ÅÉäѧÖеĸºÔðÈÎÍƽø»¹ÐèÒª¸üÇ¿ÓÐÁ¦µÄ¼à¹ÜºÍÔËÓª¿ò¼Ü¡£HIPAAºÍGDPRµÈÏÖÐз¨ÂÉÌṩÁË»ù´¡Ö¸µ¼£¬µ«Î´Õë¶ÔAIÌØÓÐÌôÕ½½øÐж¨ÖÆ£¬ÌرðÊÇÄ£ÐÍÖØѵÁ·¡¢¿É½âÊÍÐÔºÍÊý¾ÝËÝÔ´¡£ÕâЩ¼à¹Ü·¾¶Í¨³£ÓÅÏÈ¿¼ÂǾ²Ì¬ÑéÖ¤£º²¿ÊðÇ°¶Ô¹Ì¶¨Ä£ÐͽøÐе¥´ÎÆÀ¹À£¬¶øδ¿¼ÂDz¿Êðºó¸üпÉÄܵ¼ÖµÄÐÔÄܱ仯¡£ÕâÒ»¾ÖÏÞ¶Ô²¿Êðºó³ÖÐøѧϰµÄ×ÔÊÊӦģÐÍÓÈΪÖØÒª£¬ÒòΪ³ÖÐø¸üпÉÄÜÎÞ·¨ÔÚ²»Öظ´ÉóÅúÁ÷³ÌµÄÇé¿öÏÂÇáÒ×±»ÈÝÄÉ¡£ÐèÒª¹ú¼ÊºÏ×÷À´Öƶ¨ÃæÏòAIµÄÊý¾ÝÖÎÀíÖ¸ÄϺÍÂ×Àí±ê×¼£¬È·±£»¼Õß°²È«ºÍ»¥²Ù×÷ÐÔ¡£´ËÍ⣬¾¼Ã·ÖÎö¡ª¡ª°üÀ¨Ä£ÐÍѵÁ·¡¢»ù´¡ÉèÊ©ºÍÁÙ´²ÕûºÏ³É±¾¡ª¡ªÓ¦ÎªÕþ²ßºÍ²ÉÄɲßÂÔÌṩÐÅÏ¢¡£×ÝÏò¶àÖÐÐÄÑо¿ÆÀ¹Àʱ¼äЧÂÊ¡¢¿ÉÀ©Õ¹ÐԺͳ¤ÆÚ»¼Õß½á¾Ö¶ÔÓÚÔÚÏÖʵ»·¾³ÖÐÑéÖ¤ÕâЩ¹¤¾ßÖÁ¹ØÖØÒª¡£Ëæ×ÅÁÙ´²Ò½Ê¦¶ÔAIÊìϤ¶ÈµÄÌá¸ß£¬Åàѵ¼Æ»®ºÍ»ú¹¹Ö§³Ö½«È·±£×¼È·½â¶Á²¢¼õÉÙÎóÓá£ËæןßÐÔÄÜAIÄ£ÐÍÈÕÒæÈÚÈëÁÙ´²¹¤×÷Á÷³Ì£¬·ÅÉä¿ÆҽʦµÄ½ÇÉ«¿ÉÄÜ´ÓÖ÷ҪͼÏñ½â¶ÁÕßת±äΪ¸ü¾ß¼à¶½ÐÔµÄλÖ㬳䵱Ëã·¨Êä³öµÄÑéÖ¤Õß¡£\n7 ½áÂÛ\nAIÒѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧµÄ¸ñ¾Ö£¬ÔÚÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌЧÂʺÍÁÙ´²¾ö²ßÖ§³Ö£¨CDS£©·½ÃæÌṩÁËÇ°ËùδÓеĽøÕ¹¡£CNN¡¢U-Net±äÌåºÍÐÂÐË»ù´¡Ä£Ð͵ÈDL¼Ü¹¹ÔÚ¶àÖÖÓ°ÏñÈÎÎñÖÐÕ¹ÏÖ³ö׿ԽÐÔÄÜ£¬°üÀ¨²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºó·ÖÎö¡£È»¶ø£¬°éËæÕâЩ¼¼ÊõÊÕÒæ¶øÀ´µÄÊǸ´ÔÓµÄÂ×Àí¡¢¼à¹ÜºÍʵ¼ùÌôÕ½¡£Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼û¡¢¿É½âÊÍÐԺͲ»¹«Æ½»ñÈ¡µÈÎÊÌâ±ØÐëÔڹ㷺ÁÙ´²ÕûºÏ֮ǰµÃµ½½â¾ö¡£ÎȽ¡µÄÖÎÀí¿ò¼Ü¡¢Í¸Ã÷µÄÑéÖ¤ºÍ°üÈÝÐÔµÄÊý¾Ý¼¯´ú±íÐÔ¶ÔÓÚÈ·±£AIϵͳ°²È«¹«Æ½µØ·þÎñ»¼ÕßÖÁ¹ØÖØÒª¡£ÁÙ´²Ò½Ê¦¡¢Ñо¿ÈËÔ±¡¢¹¤³ÌʦºÍÕþ²ßÖƶ¨ÕßÖ®¼äµÄ³ÖÐøÐ×÷¶ÔÓÚÃֺϴ´ÐÂÓ븺ÔðÈÎʵʩ֮¼äµÄ²î¾àÖÁ¹ØÖØÒª¡£Ëæ×ÅÁìÓò³ÉÊ죬ÖصãÓ¦´Ó¸ÅÄîÑé֤׼ȷÐÔתÏò¿É½âÊÍÐÔ¡¢·º»¯ÐÔºÍÂ×Àí¹ÜÀí¡£Í¨¹ý³ÖÐøµÄ¿çѧ¿ÆºÏ×÷ºÍ¼à¶½£¬AIÔÚÉñ¾Ó°ÏñѧÖв»½öÓÐÍûÌá¸ßÕï¶Ï¾«¶È£¬»¹ÓÐÍûÒÔ¹«Æ½¿ÉÐŵķ½Ê½ÖØж¨ÒåÉñ¾»¤Àí±ê×¼¡£","excerpt":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs.","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 14247 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 14247 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":14247,"summary_length":5898,"usable_text_length":14247,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":14247,"summary_length":5898}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","summary":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs.","source":"生物通","date":"2026-09-27T01:00:54+00:00","content":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ·ÅÉä¿Æҽʦ33.3%£©£¬×÷Ϊ¸¨Öú¹¤¾ßʱÁéÃô¶ÈÏÔÖøÌá¸ß£¨Ê¹ÓÃAI 41.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs. 135, p<0.001£©¡£RauscheckerµÈÈËÆÀ¹ÀÁ˽áºÏDLºÍ±´Ò¶Ë¹ÍøÂçµÄMRI¼ø±ðÕï¶ÏAIϵͳ£¬Ëã·¨´ïµ½91%µÄÇ°ÈýλÕï¶Ï׼ȷÂÊ£¬±íÏÖÓëѧÊõÉñ¾·ÅÉä¿ÆҽʦÏ൱£¨86%; p=0.20£©£¬ÓÅÓÚסԺҽʦ£¨56%; p<0.001£©¡¢½øÐÞҽʦ£¨77%; p=0.003£©ºÍÆÕͨ·ÅÉä¿Æҽʦ£¨57%; p<0.001£©¡£\n4.2 ÁÙ´²ÊµÊ©Ó빤×÷Á÷³ÌÓ°Ïì\nÔÚ¼±ÐÔÉñ¾Ó°ÏñѧÖУ¬»ùÓÚCNNµÄÄ£ÐÍÔÚ´óѪ¹Ü±ÕÈû£¨Large Vessel Occlusion, LVO£©×äÖмì²âÖдﵽ85%µÄÁéÃô¶È£¬ÏÔÖøÓÅÓÚËæ»úÉÁÖÄ£ÐÍ£¨68%£©£¬²¢¾ßÓмÓËÙ·ÖÕïºÍÖÎÁÆʱ¼äÏßµÄDZÁ¦¡£RAPID ICH¡¢Viz.aiºÍAldoc MedicalµÈ¹¤¾ßÀûÓÃDL×Ô¶¯Ê¶±ðºÍ·ÖÀàCTÉϵijöѪ£¬×÷ΪʵʱÕï¶Ï¸¨Öú£¬Ìṩ¡°¶þ´ÎÔĶÁ¡±¡¢ÐÖúÖÊÁ¿±£Ö¤²¢°ïÖú·ÅÉä¿ÆҽʦÓÅÏÈ´¦Àí½ô¼±²¡Àý£¬¿ÉÄܼõÉÙÅжÁÑÓ³Ù¡£\n4.3 ÕæʵÊÀ½ç²ÉÓÃÓëÓû§ÈÏÖª\nº«¹ú·ÅÉä¿Æҽʦȫ¹úµ÷²éÏÔʾ£¬60.3%£¨223/370£©Òѽ«»ùÓÚAIµÄÈí¼þÄÉÈëʵ¼ù£¬Ö÷ÒªÓÃÓÚ²¡Ôî¼ì²â£¨82.1%£©¡¢Õï¶Ï¸¨Öú£¨55.2%£©ºÍͼÏñ·ÖÀࣨ55.2%£©¡£67.6%µÄÊÜ·ÃÕß×¢Òâµ½»¼Õß¹ÜÀíµÄ¸ÄÉÆ£¬85.1%¶ÔAIÐÔÄܱíʾ×ÜÌåÂúÒ⡣Ȼ¶ø£¬92%µÄÊÜ·ÃÕßÈÏΪÐèÒªÕý¹æ½ÌÓýºÍÖ¸ÄÏÒÔÈ·±£AIÊä³öµÄÊʵ±Ê¹Óúͽâ¶Á¡£\n4.4 ÁÙ´²½á¾Ö×ܽá\nÔÚ¶à¸öÁìÓò£¬AIÇý¶¯µÄÉñ¾Ó°ÏñϵͳչÏÖ³ö¸ßÕï¶Ï׼ȷÐÔ¡¢Ð§ÂʺͿÉÀ©Õ¹ÐÔ£¬ÐÔÄܳ£Óëר¼ÒÉñ¾·ÅÉä¿ÆҽʦÏ൱¡£ÆäÁÙ´²ÕûºÏÌṩÁ˼ò»¯¹¤×÷Á÷³Ì¡¢Ö§³Ö¾ö²ßºÍ¸ÄÉÆ»¼Õß½á¾ÖµÄ»ú»á¡£È»¶ø£¬ÕâЩÒæ´¦ÒÀÀµÓÚÑϸñµÄ¶àÖÐÐÄÑéÖ¤ÒÔ¼°¶Ô¿É½âÊÍÐÔ¡¢ÁÙ´²Ò½Ê¦½ÌÓýºÍÂ×ÀíÖÎÀíµÄ³ÖÐø¹Ø×¢¡£\n5 Â×Àí¿¼Á¿Óë¾ÖÏÞÐÔ\n5.1 Êý¾ÝÒþ˽ÓëÖÎÀí\nÊý¾ÝÒþ˽ÊÇAIÇý¶¯Éñ¾Ó°ÏñÖÐ×î½ôÆȵÄÂ×Àí¹ØÇÐÖ®Ò»£¬ÓÈÆäÊǵ±´óÐÍÓ°ÏñÊý¾Ý¼¯´æ´¢ÔÚ¿ç¹ú¼Ê±ß½ç¾ÛºÏÐÅÏ¢µÄÃÅ»§»òÔÆϵͳÖÐʱ¡£ÄÔ²¿É¨Ãè¾ßÓжÀÌØ·çÏÕ£¬ÒòΪ½âÆʽṹ¿ÉÓë¸öÈËÊý¾ÝÆ¥Åä´Ó¶øʵÏÖÔÙʶ±ð¡£Å·ÃËͨÓÃÊý¾Ý±£»¤ÌõÀý£¨GDPR£©Çø·Ö¸öÈËÊý¾Ý¡¢È¥±êʶ»¯Êý¾ÝºÍÍêÈ«ÄäÃûÊý¾Ý£¬¶øÖйú¸öÈËÐÅÏ¢±£»¤·¨£¨PIPL£©½«ÉúÎïʶ±ðºÍÒ½ÁÆÐÅÏ¢¹éÀàΪ¸ß¶ÈÃô¸ÐÊý¾Ý¡£È»¶ø£¬¹ú¼ÒºÍ»ú¹¹¼äÒþ˽·¨ÂɵÄÒìÖÊÐÔʹ¿ç¾³Êý¾Ý¹²Ïí¸´ÔÓ»¯¡£Áª°îѧϰ£¨FL£©Äܹ»ÔÚÎÞÐè´«ÊäÔʼÊý¾ÝµÄÇé¿öϽøÐпç»ú¹¹Ä£ÐÍѵÁ·£¬¼õÉÙ¼¯Öд洢¿âµÄÐèÇó¡£Êý¾ÝʹÓÃÐÒ飨Data Use Agreements, DUAs£©ºÍÊý¾Ý´«ÊäÐÒ飨Data Transfer Agreements, DTAs£©µÈÕýʽÐÒ鶨ÒåÁËÔðÈβ¢·ÀÖ¹ÀÄÓá£\n5.2 żȻ·¢ÏÖÓë¿É½âÊÍÐÔ\nżȻ·¢ÏֵĹÜÀí¡ª¡ªÑо¿»òÕï¶ÏÓ°ÏñÖз¢ÏÖµÄÒâÍâÒì³£¡ª¡ªÌá³öÁËÁíÒ»Â×ÀíÀ§¾³¡£AIϵͳÒò¸ßÁéÃô¶ÈºÍÐí¶àDLÄ£Ð͵ġ°ºÚÏ䡱ÌØÐÔ¶ø¼Ó¾çÁËÕâÒ»ÎÊÌ⣬ÏÞÖÆÁËÁÙ´²Ò½Ê¦½â¶ÁËã·¨ÍÆÀíµÄÄÜÁ¦¡£AIϵͳµÄ¿ª·¢ÕßÓ¦·ÅÆúÓÅÏÈ¿¼ÂÇÉÌÒµÃØÃܶø·Ç͸Ã÷ÐԵġ°ÒþÐοÆѧ¡±×ö·¨¡£¿ª·¢Õß±ØÐëÈ·±£³ÖÐø¼à²âºÍƵ·±ÓÅ»¯AIϵͳ£¬ÒÔ¸úÉϲ»¶Ï·¢Õ¹µÄÁÙ´²Êµ¼ù¡£ÁÙ´²Ò½Ê¦ÔÚ½«ÕâЩ¹¤¾ßÕûºÏµ½ÁÙ´²Êµ¼ùÖÐʱÐèÒª²Éȡƽºâ·½·¨£¬Í¬Ê±²»Ëðº¦ÆäÁÙ´²Åжϡ£½«Î±Ó°»òÕý³£±äÒìÎóʶ±ðΪ²¡Àí¿Éµ¼Ö»¼Õß½¹ÂÇ¡¢²»±ØÒªµÄËæ·Ã¼ì²é»òÎóÕï¡£¸÷˾·¨¹ÜϽÇø¼à¹Ü¿ò¼ÜµÄ²»Ò»ÖÂÐÔʹµÃ½¨Á¢±ê×¼»¯³ÌÐòÀ´¹ÜÀíÕâЩ·¢ÏÖ±äµÃÀ§ÄÑ¡£\n5.3 Ë㷨ƫ¼ûÓ빫ƽÐÔ\nË㷨ƫ¼ûÊÇAIÔÚÉñ¾Ó°ÏñÖÐÂ×ÀíÓ¦Óõĸù±¾¾ÖÏÞ¡£Ò»Ïî½üÆÚÜöÝÍ·ÖÎö·¢ÏÖ£¬97.5%µÄѵÁ·Êý¾Ý¼¯À´×Ô¸ßÊÕÈë»òÖиßÊÕÈëµØÇø£¬µ¼ÖÂϵͳÐÔȱ·¦¶àÑùÐÔ£¬Ï÷ÈõÁËÈ«ÇòÊÊÓÃÐÔ¡£Ò»ÏîAIÕï¶Ï°¢¶û´Äº£Ä¬²¡µÄÑо¿ËµÃ÷ÁËÕâһЧӦ£ºÔÚÃÀ¹ú°¢¶û´Äº£Ä¬²¡Éñ¾Ó°Ïñѧ³«Ò飨Alzheimer's Disease Neuroimaging Initiative, ADNI£©Êý¾Ý¼¯ÉÏѵÁ·µÄCNNÔÚ°Ä´óÀûÑÇAIBL¶ÓÁÐÖбíÏÖÁ¼ºÃ£¬µ«ÔÚÒâ´óÀûI-ADNIÊý¾Ý¼¯ÉÏÏÔÖø¶ñ»¯£¬×¼È·ÂʽöΪ78%¡£Ðí¶àÓÃÓÚAI¿ª·¢µÄ»ùÓÚ»úÆ÷ѧϰ£¨Machine Learning, ML£©µÄÊý¾Ý¿âÀ´×Ô¸ßÊÕÈë¹ú¼Ò£¨Å·Ö޺ͱ±ÃÀ£©£¬¶ÔÑÇÖÞ¡¢À¶¡ÃÀÖ޺ͷÇÖÞÈËȺµÄÄÉÈëÓÐÏÞ£¬Ôì³É¡°Ã÷È·µÄselection bias¡±¡£Ó¦Öƶ¨Õþ²ßÇ¿ÖÆÄÉÈëÖÖ×å¡¢Ãñ×å¡¢ÄêÁä¡¢ÐÔ±ðºÍÉç»á¾¼ÃµØλµÈÈË¿Úͳ¼Æѧ±äÁ¿ÒÔ½øÐÐÆ«¼ûÉó¼Æ¡£Ó¦²ÉÓÃFUTURE-AIÖ¸ÄϵÈÂ×Àí×¼Ôò£¬È·±£¹«Æ½ÐÔºÍÆÕ±éÐÔÔÔòÈÚÈ뿪·¢¹ý³Ì¡£ÃÀ¹ú¡°All of Us¡±Ñо¿¼Æ»®µÈ¿É×÷Ϊ³¬Ô½µØÀíºÍÉç»á¾¼Ã±ß½ç´´½¨È«ÇòÊý¾Ý¿âµÄÄ£ÐÍ¡£\n5.4 ¼à¹ÜÓëʵ¼ù¾ÖÏÞÐÔ\nÏÖÐмà¹Ü»·¾³ÉÐδÊÊÓ¦¶àÖÐÐÄAIÑо¿µÄ¸´ÔÓÐÔ¡£¹ÜÀíÁÙ´²Êý¾Ý¼¯ÊÕ¼¯¡¢Ê¹Óúͽ»»»µÄÉç»á·¨ÂÉ¿ò¼Ü²îÒì×è°Á˹ú¼ÊºÏ×÷¡£´ËÍ⣬Õë¶Ô³ÖÐø´ÓÐÂÊý¾ÝѧϰµÄ×ÔÊÊÓ¦Ëã·¨µÄÉÏÊкó¼à²â»òÑéÖ¤±ê×¼»¯³ÌÐòºÜÉÙ¡£È±·¦È«Ãæ¼à¶½Ê±£¬Â×ÀíºÍ°²È«Ê§Îó¿ÉÄÜÔÚ»¼ÕßÉ˺¦·¢ÉúÇ°²»±»·¢ÏÖ¡£\n5.5 ·¨ÂÉÔðÈÎ\nAI¸¨ÖúÉñ¾Ó°ÏñµÄÁíÒ»¸ö¹ØÇÐÊÇ·¨ÂÉÔðÈΣ¬ÒòΪҽʦ³Ðµ£Õï¶ÏÔðÈΡ£ÔðÈα»ÊÓΪÁÙ´²Ò½Ê¦ÓëË㷨ϵͳ֮¼äµÄ·Ö²¼Ê½¹¹½¨£¬·´Ó³ÁËÁÙ´²Êµ¼ùÖÐÏò¹²Ïí¾ö²ß·¶Ê½µÄת±ä¡£Îª½µµÍ·¨ÂÉ·çÏÕ£¬ÁÙ´²Ò½Ê¦±ØÐëÈ·±£AIµÄʹÓ÷ûºÏͬһר¿ÆºÏ¸ñ´ÓÒµÕߵıê×¼»¤Àíˮƽ¡£·¨ÂÉ·ÖÎö¿¼ÂÇÁ½ÖÖÇéÐΣºÒ»ÊÇҽʦ¾Ü¾øÁË·ûºÏ±ê×¼»¤ÀíµÄÕýÈ·½¨Ò飻¶þÊÇҽʦ×ñÑÁ˲»·ûºÏ±ê×¼»¤ÀíµÄ´íÎóAI½¨Òé¡£Èç¹ûAIÄܳ¬Ô½ÈËÀà¾ö²ßÄÜÁ¦£¬·¨ÂÉר¼ÒÔ¤²â¿ÉÄÜÓбØÒª²ÉÄÉAIÁÙ´²¾ö²ßÖ§³Ö£¨Clinical Decision Support, CDS£©¡£Èç¹ûAI¹¤¾ßµÄʹÓó¬³ö¼à¹ÜÊÚȨ£¨ÈçFDAÐí¿ÉºÍCE±êÖ¾£©Ö¸¶¨µÄÔ¤ÆÚÓÃ;£¬ÔðÈηçÏÕ»áÔö¼Ó£¬Òò´Ë´ÓÒµÕßÓ¦Á˽âÄ¿±êÈËȺºÍÊäÈëÊý¾ÝÒªÇóÒÔ±£³Ö·¨ÂÉÕýµ±ÐÔ¡£\n6 ÌÖÂÛ\n±¾×ÛÊöÇ¿µ÷ÁËAIºÍ»úÆ÷ѧϰ£¨ML£©ÔÚÉñ¾·ÅÉäѧÖеÄÑ¡¶¨½øÕ¹ºÍÁÙ´²Ç±Á¦£¬Ìرð¹Ø×¢¶àÖÐÐÄÑéÖ¤ºÍʵʩ¡£Ëù¿¼²ìµÄ¼Ü¹¹°üÀ¨cML¼°ÆäÑÜÉúDL¡ª¡ªÓÈÆäÊÇU-NetºÍnnU-NetµÈCNN¡ª¡ªÒÔ¼°¸üеÄTransformerºÍ»ù´¡Ä£ÐÍ¡£ÕâЩϵͳÔÚ¶àÖÖÉñ¾Ó°ÏñÓ¦ÓÃÖÐÕ¹ÏÖ³öÓÐÇ°¾°µÄÐÔÄÜ£¬´ÓÄÔÖ×ÁöºÍתÒÆÁö·Ö¸îµ½Ñª¹Ü²¡Àí¼ì²âºÍ¼ø±ðÕï¶ÏÉú³É¡£¶àÖÐÐÄÑéÖ¤Ñо¿ÈÕÒæÖ§³ÖAIÄ£ÐÍ¿çɨÃèÒÇ¡¢ÈËȺºÍÓ°ÏñÐÒéµÄ·º»¯ÐÔ£¬Í¹ÏÔÆäÎȽ¡ÁÙ´²×ª»¯µÄDZÁ¦¡£ÖµµÃ×¢ÒâµÄÊÇ£¬¾¡¹ÜAIÔÚÉñ¾·ÅÉäѧÖпìËÙÔö³¤£¬µ«Ïà¶Ô½ÏÉÙµÄÑо¿Äܳ¬Ô½µ¥ÖÐÐÄ¿ª·¢½øÈëÎȽ¡µÄ¶àÖÐÐÄÑéÖ¤£¬Õâ͹ÏÔÁË·½·¨´´ÐÂÓëÏÖʵÁÙ´²×ª»¯Ö®¼äµÄ¹Ø¼ü²î¾à¡£\n6.1 ¾ÖÏÞÐÔ\nÂ×ÀíÌôÕ½°üÀ¨¼¯ÖÐʽÊý¾ÝϵͳÖеĻ¼ÕßÒþ˽µ£ÓÇ¡¢Ëã·¨ºÍÊý¾Ý¼¯Æ«¼û£¬ÒÔ¼°GDPRºÍHIPAAµÈÊý¾Ý±£»¤¿ò¼ÜÖ´Ðв»Ò»Ö¡£¼¼ÊõºÍ·½·¨¾ÖÏÞÈÔÈ»´æÔÚ£ºµ±Ç°AIÄ£ÐÍÔÚѵÁ··½·¨¡¢Êý¾Ý¼¯×é³ÉºÍÑéÖ¤Ö¸±ê·½Ãæ±íÏÖ³öÒìÖÊÐÔ£»Ðí¶àϵͳȱ·¦¿É½âÊÍÐÔ£¬ºÜÉÙ¿¼ÂÇ»¼Õߺϲ¢Ö¢£¬ÇÒÔÚÓÐÏÞ»òÈË¿Úͳ¼ÆѧÏÁÕµÄÊý¾Ý¼¯ÉÏѵÁ·¡£È±·¦±ê×¼»¯»ù×¼ºÍ¿ÉÖظ´ÐÔÖ¸ÄϽøÒ»²½Ê¹ÁÙ´²ÆÀ¹À¸´ÔÓ»¯¡£±¾×ÛÊö±¾Éí´æÔÚÖØÒª¾ÖÏÞ£º×÷ΪÕë¶ÔÐÔ·¶Î§×ÛÊö£¬²¢·ÇÖ¼ÔÚÇ£¬ÄÉÈëÑо¿ÊýÁ¿Ïà¶Ô½ÏÉÙ·´Ó³ÁËÑϸñÄÉÈë±ê×¼¶Ô¶àÖÐÐÄÑéÖ¤µÄÌض¨¹Ø×¢£»¸÷Ñо¿¶Ô¡°¶àÖÐÐÄ¡±ÑéÖ¤¶¨ÒåµÄ¿É±äÐÔ¿ÉÄܵ¼ÖÂÒÅ©ʹÓöà»ú¹¹Êý¾Ýµ«Î´Ã÷È·ÃèÊöµÄÏà¹ØÎÄÏ×£»Ñо¿Éè¼Æ¡¢Êý¾Ý¼¯ºÍ±¨¸æÖ¸±êµÄÒìÖÊÐÔÏÞÖÆÑо¿¼äÖ±½Ó±È½Ï¡£\n6.2 ¿ÉÀ©Õ¹AIµÄ»ù´¡ÉèÊ©ÓëÕþ²ß\nAIÔÚÉñ¾Ó°ÏñÖеĿÉÀ©Õ¹²¿ÊðÐèÒªÎȽ¡µÄ»ù´¡ÉèÊ©ºÍά»¤¾«ÃܵÄÈíÓ²¼þ¡£ÔÚ»ù´¡²ãÃ棬ÕâЩϵͳÐèÒª±ê×¢Êý¾ÝÀ´²úÉú¹¦ÄÜÐÔѵÁ·Êý¾Ý¼¯£¬ÕâÐèÒªºÏ¸ñҽʦºÍר¼ÒµÄе÷Óë×Éѯ¡£ÔÚ»ú¹¹²ãÃ棬ҽԺ±ØÐëÈ·±£¾ß±¸ÔËÐÐÕâЩģÐ͵ݲȫ¼ÆËãÓ²¼þ£¬°üÀ¨´¦Àí¸ßÐÔÄܼÆËãÈÎÎñµÄ¼ÆËã»ú½ÚµãºÍͼÐδ¦Àíµ¥Ôª£¨Graphics Processing Units, GPUs£©¡£FL»¹ÐèÒªÖÐÑë¾ÛºÏ·þÎñÆ÷½øÐÐе÷ºÍÄ£Ð͸üС£ÕâЩÉ豸ÀíÏëÇé¿öÏÂÓ¦Å䱸Êʵ±µÄÈí¼þ£¬°üÀ¨Êý¾ÝÔ¤´¦Àí¹ÜµÀ¡¢ÐÅÏ¢°²È«µÄ¼ÓÃÜ·½·¨¡¢ÏµÍ³¼ä±£ÃÜÊý¾Ý½»»»µÄ°²È«²ÎÊýÐÒ顣ϵͳ±ØÐë¾ß±¸»¥²Ù×÷ÐÔ¡ª¡ª²»Í¬ÏµÍ³»òÉ豸ͨÐźͽ»»»Êý¾ÝµÄÄÜÁ¦¡ª¡ªÌرðÊÇ´ÓÓ°ÏñÉ豸´«ÊäÊý¾ÝºÍ¿çÖÐÐÄÁ¬½Ó¡£ÕâÇ¿µ÷ÁËʹÓÃҽѧÊý×Ö³ÉÏñºÍͨÐÅ£¨Digital Imaging and Communications in Medicine, DICOM£©±ê×¼½øÐд洢ºÍ½»»»ÐÒéÒÔ¼°Î¬³Ö±ê×¼»¯±ê×¢¿ò¼Ü½øÐÐÊý¾Ý±ê×¢µÄÖØÒªÐÔ¡£Ó²¼þÒìÖÊÐÔÒ²ÒýÈëÁË´àÈõÐÔ£¬Ôì³ÉѵÁ·²î¾àºÍ´ú±íÐÔ²»×㣬Òò´Ë¿çÓ°Ïñģ̬µÄÊý¾Ýе÷£¨ÈçMRIÊý¾Ý¼¯µÄÏñËØÇ¿¶È¹éÒ»»¯¼¼Êõ£©¾ßÓмÛÖµ¡£Õþ²ß¿ò¼ÜͬÑù¹Ø¼ü£¬ÓÃÓÚʵʩ¿ÉÀ©Õ¹Êý¾Ý¼¯µÄÖÎÀí¡¢×ñÊØÒþ˽Á¢·¨ºÍ×ÊÖú¼¼Êõ»ù´¡ÉèÊ©¡£\n6.3 δÀ´¿¼Á¿\nδÀ´Ñо¿Ó¦¾Û½¹¶àģ̬ÕûºÏ£¬½«¶àÖÖÓ°Ïñģ̬£¨ÈçMRI¡¢CT¡¢PET£©ÓëÁÙ´²ºÍÒÅ´«Êý¾Ý½áºÏ£¬ÒÔÌá¸ßÕï¶Ï׼ȷÐÔºÍÇé¾³Àí½â¡£ADNIµÈ¿ª·Å»ñÈ¡Êý¾Ý¼¯Ó¦À©Õ¹ÒÔ½â¾öÊý¾ÝÒìÖÊÐÔ²¢Í¨¹ýÈ«Çò´ú±íÐÔ´Ù½øËã·¨¹«Æ½ÐÔ¡£ÎªÆ½ºâÒþ˽ÓëÐÔÄÜ£¬Áª°îѧϰ£¨FL£©ºÍÎ޼ලÓòÊÊÓ¦£¨Unsupervised Domain Adaptation, UDA£©ÒÑ»ñµÃ¹Ø×¢¡£FLʵÏÖÎÞÐè¹²ÏíÔʼÊý¾ÝµÄÈ¥ÖÐÐÄ»¯Ä£ÐÍѵÁ·£¬¶øUDAÔÊÐíÄ£ÐÍͨ¹ýÀûÓÃÏÈǰѧϰ·º»¯µ½Î´±ê×¢»òÓòÆ«ÒƵÄÊý¾Ý¼¯¡£UDA¿É»º½â¡°ÓòÆ«ÒÆ¡±ÎÊÌ⣬ʹģÐÍÊÊÓ¦ºÍÓÅ»¯µ½¶à¸ö²»Í¬Êý¾ÝÔ´ºÍÓò£¬Ãֺϱê×¢ÄÚ²¿Ô´ÓëÐÂÍⲿ¶ÓÁÐÖ®¼äµÄ²î¾à¡£È»¶ø£¬È¥ÖÐÐÄ»¯¿ÉÄÜ·Å´óÊý¾Ý¼¯±äÒìÐÔ²¢Ê¹ÖÊÁ¿¿ØÖƸ´ÔÓ»¯¡£»¹Ó¦¿¼ÂDZê×¼»¯³ÉÏñÐÒéÒÔÔÚÊäÈë²ãÃæ½â¾ö²»Ò»ÖÂÐÔ¡£ÁíÒ»ÖÖ·½·¨¡ª¡ªÊ¹ÓÃÄäÃû»¯¶à»ú¹¹Êý¾Ý½øÐа²È«¼¯ÖÐѵÁ·¡ª¡ª¿ÉÔÚͨ¹ý±ê×¼»¯Ô¤´¦ÀíºÍÖÊÁ¿±£Ö¤¸ÄÉÆÒ»ÖÂÐÔµÄͬʱ±£³ÖÒþ˽¡£½üÆÚ»¹Ìá³öÁË¡°Áª°îÓòÊÊÓ¦¡±£¬¼´ÑµÁ·Ò»¸öͨÓÃÄ£ÐͲ¢¸¨ÒÔ¸üרҵ»¯µÄÓòµ÷ÓÅ˽ÓÐÄ£ÐÍ£¬ËüÃÇÏ໥½»»¥ÒÔ´ï³É¹²Í¬Êä³ö¡£AIÔÚÉñ¾·ÅÉäѧÖеĸºÔðÈÎÍƽø»¹ÐèÒª¸üÇ¿ÓÐÁ¦µÄ¼à¹ÜºÍÔËÓª¿ò¼Ü¡£HIPAAºÍGDPRµÈÏÖÐз¨ÂÉÌṩÁË»ù´¡Ö¸µ¼£¬µ«Î´Õë¶ÔAIÌØÓÐÌôÕ½½øÐж¨ÖÆ£¬ÌرðÊÇÄ£ÐÍÖØѵÁ·¡¢¿É½âÊÍÐÔºÍÊý¾ÝËÝÔ´¡£ÕâЩ¼à¹Ü·¾¶Í¨³£ÓÅÏÈ¿¼ÂǾ²Ì¬ÑéÖ¤£º²¿ÊðÇ°¶Ô¹Ì¶¨Ä£ÐͽøÐе¥´ÎÆÀ¹À£¬¶øδ¿¼ÂDz¿Êðºó¸üпÉÄܵ¼ÖµÄÐÔÄܱ仯¡£ÕâÒ»¾ÖÏÞ¶Ô²¿Êðºó³ÖÐøѧϰµÄ×ÔÊÊӦģÐÍÓÈΪÖØÒª£¬ÒòΪ³ÖÐø¸üпÉÄÜÎÞ·¨ÔÚ²»Öظ´ÉóÅúÁ÷³ÌµÄÇé¿öÏÂÇáÒ×±»ÈÝÄÉ¡£ÐèÒª¹ú¼ÊºÏ×÷À´Öƶ¨ÃæÏòAIµÄÊý¾ÝÖÎÀíÖ¸ÄϺÍÂ×Àí±ê×¼£¬È·±£»¼Õß°²È«ºÍ»¥²Ù×÷ÐÔ¡£´ËÍ⣬¾¼Ã·ÖÎö¡ª¡ª°üÀ¨Ä£ÐÍѵÁ·¡¢»ù´¡ÉèÊ©ºÍÁÙ´²ÕûºÏ³É±¾¡ª¡ªÓ¦ÎªÕþ²ßºÍ²ÉÄɲßÂÔÌṩÐÅÏ¢¡£×ÝÏò¶àÖÐÐÄÑо¿ÆÀ¹Àʱ¼äЧÂÊ¡¢¿ÉÀ©Õ¹ÐԺͳ¤ÆÚ»¼Õß½á¾Ö¶ÔÓÚÔÚÏÖʵ»·¾³ÖÐÑéÖ¤ÕâЩ¹¤¾ßÖÁ¹ØÖØÒª¡£Ëæ×ÅÁÙ´²Ò½Ê¦¶ÔAIÊìϤ¶ÈµÄÌá¸ß£¬Åàѵ¼Æ»®ºÍ»ú¹¹Ö§³Ö½«È·±£×¼È·½â¶Á²¢¼õÉÙÎóÓá£ËæןßÐÔÄÜAIÄ£ÐÍÈÕÒæÈÚÈëÁÙ´²¹¤×÷Á÷³Ì£¬·ÅÉä¿ÆҽʦµÄ½ÇÉ«¿ÉÄÜ´ÓÖ÷ҪͼÏñ½â¶ÁÕßת±äΪ¸ü¾ß¼à¶½ÐÔµÄλÖ㬳䵱Ëã·¨Êä³öµÄÑéÖ¤Õß¡£\n7 ½áÂÛ\nAIÒѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧµÄ¸ñ¾Ö£¬ÔÚÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌЧÂʺÍÁÙ´²¾ö²ßÖ§³Ö£¨CDS£©·½ÃæÌṩÁËÇ°ËùδÓеĽøÕ¹¡£CNN¡¢U-Net±äÌåºÍÐÂÐË»ù´¡Ä£Ð͵ÈDL¼Ü¹¹ÔÚ¶àÖÖÓ°ÏñÈÎÎñÖÐÕ¹ÏÖ³ö׿ԽÐÔÄÜ£¬°üÀ¨²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºó·ÖÎö¡£È»¶ø£¬°éËæÕâЩ¼¼ÊõÊÕÒæ¶øÀ´µÄÊǸ´ÔÓµÄÂ×Àí¡¢¼à¹ÜºÍʵ¼ùÌôÕ½¡£Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼û¡¢¿É½âÊÍÐԺͲ»¹«Æ½»ñÈ¡µÈÎÊÌâ±ØÐëÔڹ㷺ÁÙ´²ÕûºÏ֮ǰµÃµ½½â¾ö¡£ÎȽ¡µÄÖÎÀí¿ò¼Ü¡¢Í¸Ã÷µÄÑéÖ¤ºÍ°üÈÝÐÔµÄÊý¾Ý¼¯´ú±íÐÔ¶ÔÓÚÈ·±£AIϵͳ°²È«¹«Æ½µØ·þÎñ»¼ÕßÖÁ¹ØÖØÒª¡£ÁÙ´²Ò½Ê¦¡¢Ñо¿ÈËÔ±¡¢¹¤³ÌʦºÍÕþ²ßÖƶ¨ÕßÖ®¼äµÄ³ÖÐøÐ×÷¶ÔÓÚÃֺϴ´ÐÂÓ븺ÔðÈÎʵʩ֮¼äµÄ²î¾àÖÁ¹ØÖØÒª¡£Ëæ×ÅÁìÓò³ÉÊ죬ÖصãÓ¦´Ó¸ÅÄîÑé֤׼ȷÐÔתÏò¿É½âÊÍÐÔ¡¢·º»¯ÐÔºÍÂ×Àí¹ÜÀí¡£Í¨¹ý³ÖÐøµÄ¿çѧ¿ÆºÏ×÷ºÍ¼à¶½£¬AIÔÚÉñ¾Ó°ÏñѧÖв»½öÓÐÍûÌá¸ßÕï¶Ï¾«¶È£¬»¹ÓÐÍûÒÔ¹«Æ½¿ÉÐŵķ½Ê½ÖØж¨ÒåÉñ¾»¤Àí±ê×¼¡£","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 14247 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 14247 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":14247,"summary_length":5898,"usable_text_length":14247,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":14247,"summary_length":5898}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/90989","export_markdown":"/api/items/90989/export?format=markdown","export_json":"/api/items/90989/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-9/20260927000425378.htm"},"formats":{"full":{"id":90989,"title":"人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","source":"生物通","author":null,"published_at":"2026-09-27T01:00:54+00:00","locale":"zh","topic":"ai","tags":[],"excerpt":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs.","full_text":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ·ÅÉä¿Æҽʦ33.3%£©£¬×÷Ϊ¸¨Öú¹¤¾ßʱÁéÃô¶ÈÏÔÖøÌá¸ß£¨Ê¹ÓÃAI 41.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs. 135, p<0.001£©¡£RauscheckerµÈÈËÆÀ¹ÀÁ˽áºÏDLºÍ±´Ò¶Ë¹ÍøÂçµÄMRI¼ø±ðÕï¶ÏAIϵͳ£¬Ëã·¨´ïµ½91%µÄÇ°ÈýλÕï¶Ï׼ȷÂÊ£¬±íÏÖÓëѧÊõÉñ¾·ÅÉä¿ÆҽʦÏ൱£¨86%; p=0.20£©£¬ÓÅÓÚסԺҽʦ£¨56%; p<0.001£©¡¢½øÐÞҽʦ£¨77%; p=0.003£©ºÍÆÕͨ·ÅÉä¿Æҽʦ£¨57%; p<0.001£©¡£\n4.2 ÁÙ´²ÊµÊ©Ó빤×÷Á÷³ÌÓ°Ïì\nÔÚ¼±ÐÔÉñ¾Ó°ÏñѧÖУ¬»ùÓÚCNNµÄÄ£ÐÍÔÚ´óѪ¹Ü±ÕÈû£¨Large Vessel Occlusion, LVO£©×äÖмì²âÖдﵽ85%µÄÁéÃô¶È£¬ÏÔÖøÓÅÓÚËæ»úÉÁÖÄ£ÐÍ£¨68%£©£¬²¢¾ßÓмÓËÙ·ÖÕïºÍÖÎÁÆʱ¼äÏßµÄDZÁ¦¡£RAPID ICH¡¢Viz.aiºÍAldoc MedicalµÈ¹¤¾ßÀûÓÃDL×Ô¶¯Ê¶±ðºÍ·ÖÀàCTÉϵijöѪ£¬×÷ΪʵʱÕï¶Ï¸¨Öú£¬Ìṩ¡°¶þ´ÎÔĶÁ¡±¡¢ÐÖúÖÊÁ¿±£Ö¤²¢°ïÖú·ÅÉä¿ÆҽʦÓÅÏÈ´¦Àí½ô¼±²¡Àý£¬¿ÉÄܼõÉÙÅжÁÑÓ³Ù¡£\n4.3 ÕæʵÊÀ½ç²ÉÓÃÓëÓû§ÈÏÖª\nº«¹ú·ÅÉä¿Æҽʦȫ¹úµ÷²éÏÔʾ£¬60.3%£¨223/370£©Òѽ«»ùÓÚAIµÄÈí¼þÄÉÈëʵ¼ù£¬Ö÷ÒªÓÃÓÚ²¡Ôî¼ì²â£¨82.1%£©¡¢Õï¶Ï¸¨Öú£¨55.2%£©ºÍͼÏñ·ÖÀࣨ55.2%£©¡£67.6%µÄÊÜ·ÃÕß×¢Òâµ½»¼Õß¹ÜÀíµÄ¸ÄÉÆ£¬85.1%¶ÔAIÐÔÄܱíʾ×ÜÌåÂúÒ⡣Ȼ¶ø£¬92%µÄÊÜ·ÃÕßÈÏΪÐèÒªÕý¹æ½ÌÓýºÍÖ¸ÄÏÒÔÈ·±£AIÊä³öµÄÊʵ±Ê¹Óúͽâ¶Á¡£\n4.4 ÁÙ´²½á¾Ö×ܽá\nÔÚ¶à¸öÁìÓò£¬AIÇý¶¯µÄÉñ¾Ó°ÏñϵͳչÏÖ³ö¸ßÕï¶Ï׼ȷÐÔ¡¢Ð§ÂʺͿÉÀ©Õ¹ÐÔ£¬ÐÔÄܳ£Óëר¼ÒÉñ¾·ÅÉä¿ÆҽʦÏ൱¡£ÆäÁÙ´²ÕûºÏÌṩÁ˼ò»¯¹¤×÷Á÷³Ì¡¢Ö§³Ö¾ö²ßºÍ¸ÄÉÆ»¼Õß½á¾ÖµÄ»ú»á¡£È»¶ø£¬ÕâЩÒæ´¦ÒÀÀµÓÚÑϸñµÄ¶àÖÐÐÄÑéÖ¤ÒÔ¼°¶Ô¿É½âÊÍÐÔ¡¢ÁÙ´²Ò½Ê¦½ÌÓýºÍÂ×ÀíÖÎÀíµÄ³ÖÐø¹Ø×¢¡£\n5 Â×Àí¿¼Á¿Óë¾ÖÏÞÐÔ\n5.1 Êý¾ÝÒþ˽ÓëÖÎÀí\nÊý¾ÝÒþ˽ÊÇAIÇý¶¯Éñ¾Ó°ÏñÖÐ×î½ôÆȵÄÂ×Àí¹ØÇÐÖ®Ò»£¬ÓÈÆäÊǵ±´óÐÍÓ°ÏñÊý¾Ý¼¯´æ´¢ÔÚ¿ç¹ú¼Ê±ß½ç¾ÛºÏÐÅÏ¢µÄÃÅ»§»òÔÆϵͳÖÐʱ¡£ÄÔ²¿É¨Ãè¾ßÓжÀÌØ·çÏÕ£¬ÒòΪ½âÆʽṹ¿ÉÓë¸öÈËÊý¾ÝÆ¥Åä´Ó¶øʵÏÖÔÙʶ±ð¡£Å·ÃËͨÓÃÊý¾Ý±£»¤ÌõÀý£¨GDPR£©Çø·Ö¸öÈËÊý¾Ý¡¢È¥±êʶ»¯Êý¾ÝºÍÍêÈ«ÄäÃûÊý¾Ý£¬¶øÖйú¸öÈËÐÅÏ¢±£»¤·¨£¨PIPL£©½«ÉúÎïʶ±ðºÍÒ½ÁÆÐÅÏ¢¹éÀàΪ¸ß¶ÈÃô¸ÐÊý¾Ý¡£È»¶ø£¬¹ú¼ÒºÍ»ú¹¹¼äÒþ˽·¨ÂɵÄÒìÖÊÐÔʹ¿ç¾³Êý¾Ý¹²Ïí¸´ÔÓ»¯¡£Áª°îѧϰ£¨FL£©Äܹ»ÔÚÎÞÐè´«ÊäÔʼÊý¾ÝµÄÇé¿öϽøÐпç»ú¹¹Ä£ÐÍѵÁ·£¬¼õÉÙ¼¯Öд洢¿âµÄÐèÇó¡£Êý¾ÝʹÓÃÐÒ飨Data Use Agreements, DUAs£©ºÍÊý¾Ý´«ÊäÐÒ飨Data Transfer Agreements, DTAs£©µÈÕýʽÐÒ鶨ÒåÁËÔðÈβ¢·ÀÖ¹ÀÄÓá£\n5.2 żȻ·¢ÏÖÓë¿É½âÊÍÐÔ\nżȻ·¢ÏֵĹÜÀí¡ª¡ªÑо¿»òÕï¶ÏÓ°ÏñÖз¢ÏÖµÄÒâÍâÒì³£¡ª¡ªÌá³öÁËÁíÒ»Â×ÀíÀ§¾³¡£AIϵͳÒò¸ßÁéÃô¶ÈºÍÐí¶àDLÄ£Ð͵ġ°ºÚÏ䡱ÌØÐÔ¶ø¼Ó¾çÁËÕâÒ»ÎÊÌ⣬ÏÞÖÆÁËÁÙ´²Ò½Ê¦½â¶ÁËã·¨ÍÆÀíµÄÄÜÁ¦¡£AIϵͳµÄ¿ª·¢ÕßÓ¦·ÅÆúÓÅÏÈ¿¼ÂÇÉÌÒµÃØÃܶø·Ç͸Ã÷ÐԵġ°ÒþÐοÆѧ¡±×ö·¨¡£¿ª·¢Õß±ØÐëÈ·±£³ÖÐø¼à²âºÍƵ·±ÓÅ»¯AIϵͳ£¬ÒÔ¸úÉϲ»¶Ï·¢Õ¹µÄÁÙ´²Êµ¼ù¡£ÁÙ´²Ò½Ê¦ÔÚ½«ÕâЩ¹¤¾ßÕûºÏµ½ÁÙ´²Êµ¼ùÖÐʱÐèÒª²Éȡƽºâ·½·¨£¬Í¬Ê±²»Ëðº¦ÆäÁÙ´²Åжϡ£½«Î±Ó°»òÕý³£±äÒìÎóʶ±ðΪ²¡Àí¿Éµ¼Ö»¼Õß½¹ÂÇ¡¢²»±ØÒªµÄËæ·Ã¼ì²é»òÎóÕï¡£¸÷˾·¨¹ÜϽÇø¼à¹Ü¿ò¼ÜµÄ²»Ò»ÖÂÐÔʹµÃ½¨Á¢±ê×¼»¯³ÌÐòÀ´¹ÜÀíÕâЩ·¢ÏÖ±äµÃÀ§ÄÑ¡£\n5.3 Ë㷨ƫ¼ûÓ빫ƽÐÔ\nË㷨ƫ¼ûÊÇAIÔÚÉñ¾Ó°ÏñÖÐÂ×ÀíÓ¦Óõĸù±¾¾ÖÏÞ¡£Ò»Ïî½üÆÚÜöÝÍ·ÖÎö·¢ÏÖ£¬97.5%µÄѵÁ·Êý¾Ý¼¯À´×Ô¸ßÊÕÈë»òÖиßÊÕÈëµØÇø£¬µ¼ÖÂϵͳÐÔȱ·¦¶àÑùÐÔ£¬Ï÷ÈõÁËÈ«ÇòÊÊÓÃÐÔ¡£Ò»ÏîAIÕï¶Ï°¢¶û´Äº£Ä¬²¡µÄÑо¿ËµÃ÷ÁËÕâһЧӦ£ºÔÚÃÀ¹ú°¢¶û´Äº£Ä¬²¡Éñ¾Ó°Ïñѧ³«Ò飨Alzheimer's Disease Neuroimaging Initiative, ADNI£©Êý¾Ý¼¯ÉÏѵÁ·µÄCNNÔÚ°Ä´óÀûÑÇAIBL¶ÓÁÐÖбíÏÖÁ¼ºÃ£¬µ«ÔÚÒâ´óÀûI-ADNIÊý¾Ý¼¯ÉÏÏÔÖø¶ñ»¯£¬×¼È·ÂʽöΪ78%¡£Ðí¶àÓÃÓÚAI¿ª·¢µÄ»ùÓÚ»úÆ÷ѧϰ£¨Machine Learning, ML£©µÄÊý¾Ý¿âÀ´×Ô¸ßÊÕÈë¹ú¼Ò£¨Å·Ö޺ͱ±ÃÀ£©£¬¶ÔÑÇÖÞ¡¢À¶¡ÃÀÖ޺ͷÇÖÞÈËȺµÄÄÉÈëÓÐÏÞ£¬Ôì³É¡°Ã÷È·µÄselection bias¡±¡£Ó¦Öƶ¨Õþ²ßÇ¿ÖÆÄÉÈëÖÖ×å¡¢Ãñ×å¡¢ÄêÁä¡¢ÐÔ±ðºÍÉç»á¾¼ÃµØλµÈÈË¿Úͳ¼Æѧ±äÁ¿ÒÔ½øÐÐÆ«¼ûÉó¼Æ¡£Ó¦²ÉÓÃFUTURE-AIÖ¸ÄϵÈÂ×Àí×¼Ôò£¬È·±£¹«Æ½ÐÔºÍÆÕ±éÐÔÔÔòÈÚÈ뿪·¢¹ý³Ì¡£ÃÀ¹ú¡°All of Us¡±Ñо¿¼Æ»®µÈ¿É×÷Ϊ³¬Ô½µØÀíºÍÉç»á¾¼Ã±ß½ç´´½¨È«ÇòÊý¾Ý¿âµÄÄ£ÐÍ¡£\n5.4 ¼à¹ÜÓëʵ¼ù¾ÖÏÞÐÔ\nÏÖÐмà¹Ü»·¾³ÉÐδÊÊÓ¦¶àÖÐÐÄAIÑо¿µÄ¸´ÔÓÐÔ¡£¹ÜÀíÁÙ´²Êý¾Ý¼¯ÊÕ¼¯¡¢Ê¹Óúͽ»»»µÄÉç»á·¨ÂÉ¿ò¼Ü²îÒì×è°Á˹ú¼ÊºÏ×÷¡£´ËÍ⣬Õë¶Ô³ÖÐø´ÓÐÂÊý¾ÝѧϰµÄ×ÔÊÊÓ¦Ëã·¨µÄÉÏÊкó¼à²â»òÑéÖ¤±ê×¼»¯³ÌÐòºÜÉÙ¡£È±·¦È«Ãæ¼à¶½Ê±£¬Â×ÀíºÍ°²È«Ê§Îó¿ÉÄÜÔÚ»¼ÕßÉ˺¦·¢ÉúÇ°²»±»·¢ÏÖ¡£\n5.5 ·¨ÂÉÔðÈÎ\nAI¸¨ÖúÉñ¾Ó°ÏñµÄÁíÒ»¸ö¹ØÇÐÊÇ·¨ÂÉÔðÈΣ¬ÒòΪҽʦ³Ðµ£Õï¶ÏÔðÈΡ£ÔðÈα»ÊÓΪÁÙ´²Ò½Ê¦ÓëË㷨ϵͳ֮¼äµÄ·Ö²¼Ê½¹¹½¨£¬·´Ó³ÁËÁÙ´²Êµ¼ùÖÐÏò¹²Ïí¾ö²ß·¶Ê½µÄת±ä¡£Îª½µµÍ·¨ÂÉ·çÏÕ£¬ÁÙ´²Ò½Ê¦±ØÐëÈ·±£AIµÄʹÓ÷ûºÏͬһר¿ÆºÏ¸ñ´ÓÒµÕߵıê×¼»¤Àíˮƽ¡£·¨ÂÉ·ÖÎö¿¼ÂÇÁ½ÖÖÇéÐΣºÒ»ÊÇҽʦ¾Ü¾øÁË·ûºÏ±ê×¼»¤ÀíµÄÕýÈ·½¨Ò飻¶þÊÇҽʦ×ñÑÁ˲»·ûºÏ±ê×¼»¤ÀíµÄ´íÎóAI½¨Òé¡£Èç¹ûAIÄܳ¬Ô½ÈËÀà¾ö²ßÄÜÁ¦£¬·¨ÂÉר¼ÒÔ¤²â¿ÉÄÜÓбØÒª²ÉÄÉAIÁÙ´²¾ö²ßÖ§³Ö£¨Clinical Decision Support, CDS£©¡£Èç¹ûAI¹¤¾ßµÄʹÓó¬³ö¼à¹ÜÊÚȨ£¨ÈçFDAÐí¿ÉºÍCE±êÖ¾£©Ö¸¶¨µÄÔ¤ÆÚÓÃ;£¬ÔðÈηçÏÕ»áÔö¼Ó£¬Òò´Ë´ÓÒµÕßÓ¦Á˽âÄ¿±êÈËȺºÍÊäÈëÊý¾ÝÒªÇóÒÔ±£³Ö·¨ÂÉÕýµ±ÐÔ¡£\n6 ÌÖÂÛ\n±¾×ÛÊöÇ¿µ÷ÁËAIºÍ»úÆ÷ѧϰ£¨ML£©ÔÚÉñ¾·ÅÉäѧÖеÄÑ¡¶¨½øÕ¹ºÍÁÙ´²Ç±Á¦£¬Ìرð¹Ø×¢¶àÖÐÐÄÑéÖ¤ºÍʵʩ¡£Ëù¿¼²ìµÄ¼Ü¹¹°üÀ¨cML¼°ÆäÑÜÉúDL¡ª¡ªÓÈÆäÊÇU-NetºÍnnU-NetµÈCNN¡ª¡ªÒÔ¼°¸üеÄTransformerºÍ»ù´¡Ä£ÐÍ¡£ÕâЩϵͳÔÚ¶àÖÖÉñ¾Ó°ÏñÓ¦ÓÃÖÐÕ¹ÏÖ³öÓÐÇ°¾°µÄÐÔÄÜ£¬´ÓÄÔÖ×ÁöºÍתÒÆÁö·Ö¸îµ½Ñª¹Ü²¡Àí¼ì²âºÍ¼ø±ðÕï¶ÏÉú³É¡£¶àÖÐÐÄÑéÖ¤Ñо¿ÈÕÒæÖ§³ÖAIÄ£ÐÍ¿çɨÃèÒÇ¡¢ÈËȺºÍÓ°ÏñÐÒéµÄ·º»¯ÐÔ£¬Í¹ÏÔÆäÎȽ¡ÁÙ´²×ª»¯µÄDZÁ¦¡£ÖµµÃ×¢ÒâµÄÊÇ£¬¾¡¹ÜAIÔÚÉñ¾·ÅÉäѧÖпìËÙÔö³¤£¬µ«Ïà¶Ô½ÏÉÙµÄÑо¿Äܳ¬Ô½µ¥ÖÐÐÄ¿ª·¢½øÈëÎȽ¡µÄ¶àÖÐÐÄÑéÖ¤£¬Õâ͹ÏÔÁË·½·¨´´ÐÂÓëÏÖʵÁÙ´²×ª»¯Ö®¼äµÄ¹Ø¼ü²î¾à¡£\n6.1 ¾ÖÏÞÐÔ\nÂ×ÀíÌôÕ½°üÀ¨¼¯ÖÐʽÊý¾ÝϵͳÖеĻ¼ÕßÒþ˽µ£ÓÇ¡¢Ëã·¨ºÍÊý¾Ý¼¯Æ«¼û£¬ÒÔ¼°GDPRºÍHIPAAµÈÊý¾Ý±£»¤¿ò¼ÜÖ´Ðв»Ò»Ö¡£¼¼ÊõºÍ·½·¨¾ÖÏÞÈÔÈ»´æÔÚ£ºµ±Ç°AIÄ£ÐÍÔÚѵÁ··½·¨¡¢Êý¾Ý¼¯×é³ÉºÍÑéÖ¤Ö¸±ê·½Ãæ±íÏÖ³öÒìÖÊÐÔ£»Ðí¶àϵͳȱ·¦¿É½âÊÍÐÔ£¬ºÜÉÙ¿¼ÂÇ»¼Õߺϲ¢Ö¢£¬ÇÒÔÚÓÐÏÞ»òÈË¿Úͳ¼ÆѧÏÁÕµÄÊý¾Ý¼¯ÉÏѵÁ·¡£È±·¦±ê×¼»¯»ù×¼ºÍ¿ÉÖظ´ÐÔÖ¸ÄϽøÒ»²½Ê¹ÁÙ´²ÆÀ¹À¸´ÔÓ»¯¡£±¾×ÛÊö±¾Éí´æÔÚÖØÒª¾ÖÏÞ£º×÷ΪÕë¶ÔÐÔ·¶Î§×ÛÊö£¬²¢·ÇÖ¼ÔÚÇ£¬ÄÉÈëÑо¿ÊýÁ¿Ïà¶Ô½ÏÉÙ·´Ó³ÁËÑϸñÄÉÈë±ê×¼¶Ô¶àÖÐÐÄÑéÖ¤µÄÌض¨¹Ø×¢£»¸÷Ñо¿¶Ô¡°¶àÖÐÐÄ¡±ÑéÖ¤¶¨ÒåµÄ¿É±äÐÔ¿ÉÄܵ¼ÖÂÒÅ©ʹÓöà»ú¹¹Êý¾Ýµ«Î´Ã÷È·ÃèÊöµÄÏà¹ØÎÄÏ×£»Ñо¿Éè¼Æ¡¢Êý¾Ý¼¯ºÍ±¨¸æÖ¸±êµÄÒìÖÊÐÔÏÞÖÆÑо¿¼äÖ±½Ó±È½Ï¡£\n6.2 ¿ÉÀ©Õ¹AIµÄ»ù´¡ÉèÊ©ÓëÕþ²ß\nAIÔÚÉñ¾Ó°ÏñÖеĿÉÀ©Õ¹²¿ÊðÐèÒªÎȽ¡µÄ»ù´¡ÉèÊ©ºÍά»¤¾«ÃܵÄÈíÓ²¼þ¡£ÔÚ»ù´¡²ãÃ棬ÕâЩϵͳÐèÒª±ê×¢Êý¾ÝÀ´²úÉú¹¦ÄÜÐÔѵÁ·Êý¾Ý¼¯£¬ÕâÐèÒªºÏ¸ñҽʦºÍר¼ÒµÄе÷Óë×Éѯ¡£ÔÚ»ú¹¹²ãÃ棬ҽԺ±ØÐëÈ·±£¾ß±¸ÔËÐÐÕâЩģÐ͵ݲȫ¼ÆËãÓ²¼þ£¬°üÀ¨´¦Àí¸ßÐÔÄܼÆËãÈÎÎñµÄ¼ÆËã»ú½ÚµãºÍͼÐδ¦Àíµ¥Ôª£¨Graphics Processing Units, GPUs£©¡£FL»¹ÐèÒªÖÐÑë¾ÛºÏ·þÎñÆ÷½øÐÐе÷ºÍÄ£Ð͸üС£ÕâЩÉ豸ÀíÏëÇé¿öÏÂÓ¦Å䱸Êʵ±µÄÈí¼þ£¬°üÀ¨Êý¾ÝÔ¤´¦Àí¹ÜµÀ¡¢ÐÅÏ¢°²È«µÄ¼ÓÃÜ·½·¨¡¢ÏµÍ³¼ä±£ÃÜÊý¾Ý½»»»µÄ°²È«²ÎÊýÐÒ顣ϵͳ±ØÐë¾ß±¸»¥²Ù×÷ÐÔ¡ª¡ª²»Í¬ÏµÍ³»òÉ豸ͨÐźͽ»»»Êý¾ÝµÄÄÜÁ¦¡ª¡ªÌرðÊÇ´ÓÓ°ÏñÉ豸´«ÊäÊý¾ÝºÍ¿çÖÐÐÄÁ¬½Ó¡£ÕâÇ¿µ÷ÁËʹÓÃҽѧÊý×Ö³ÉÏñºÍͨÐÅ£¨Digital Imaging and Communications in Medicine, DICOM£©±ê×¼½øÐд洢ºÍ½»»»ÐÒéÒÔ¼°Î¬³Ö±ê×¼»¯±ê×¢¿ò¼Ü½øÐÐÊý¾Ý±ê×¢µÄÖØÒªÐÔ¡£Ó²¼þÒìÖÊÐÔÒ²ÒýÈëÁË´àÈõÐÔ£¬Ôì³ÉѵÁ·²î¾àºÍ´ú±íÐÔ²»×㣬Òò´Ë¿çÓ°Ïñģ̬µÄÊý¾Ýе÷£¨ÈçMRIÊý¾Ý¼¯µÄÏñËØÇ¿¶È¹éÒ»»¯¼¼Êõ£©¾ßÓмÛÖµ¡£Õþ²ß¿ò¼ÜͬÑù¹Ø¼ü£¬ÓÃÓÚʵʩ¿ÉÀ©Õ¹Êý¾Ý¼¯µÄÖÎÀí¡¢×ñÊØÒþ˽Á¢·¨ºÍ×ÊÖú¼¼Êõ»ù´¡ÉèÊ©¡£\n6.3 δÀ´¿¼Á¿\nδÀ´Ñо¿Ó¦¾Û½¹¶àģ̬ÕûºÏ£¬½«¶àÖÖÓ°Ïñģ̬£¨ÈçMRI¡¢CT¡¢PET£©ÓëÁÙ´²ºÍÒÅ´«Êý¾Ý½áºÏ£¬ÒÔÌá¸ßÕï¶Ï׼ȷÐÔºÍÇé¾³Àí½â¡£ADNIµÈ¿ª·Å»ñÈ¡Êý¾Ý¼¯Ó¦À©Õ¹ÒÔ½â¾öÊý¾ÝÒìÖÊÐÔ²¢Í¨¹ýÈ«Çò´ú±íÐÔ´Ù½øËã·¨¹«Æ½ÐÔ¡£ÎªÆ½ºâÒþ˽ÓëÐÔÄÜ£¬Áª°îѧϰ£¨FL£©ºÍÎ޼ලÓòÊÊÓ¦£¨Unsupervised Domain Adaptation, UDA£©ÒÑ»ñµÃ¹Ø×¢¡£FLʵÏÖÎÞÐè¹²ÏíÔʼÊý¾ÝµÄÈ¥ÖÐÐÄ»¯Ä£ÐÍѵÁ·£¬¶øUDAÔÊÐíÄ£ÐÍͨ¹ýÀûÓÃÏÈǰѧϰ·º»¯µ½Î´±ê×¢»òÓòÆ«ÒƵÄÊý¾Ý¼¯¡£UDA¿É»º½â¡°ÓòÆ«ÒÆ¡±ÎÊÌ⣬ʹģÐÍÊÊÓ¦ºÍÓÅ»¯µ½¶à¸ö²»Í¬Êý¾ÝÔ´ºÍÓò£¬Ãֺϱê×¢ÄÚ²¿Ô´ÓëÐÂÍⲿ¶ÓÁÐÖ®¼äµÄ²î¾à¡£È»¶ø£¬È¥ÖÐÐÄ»¯¿ÉÄÜ·Å´óÊý¾Ý¼¯±äÒìÐÔ²¢Ê¹ÖÊÁ¿¿ØÖƸ´ÔÓ»¯¡£»¹Ó¦¿¼ÂDZê×¼»¯³ÉÏñÐÒéÒÔÔÚÊäÈë²ãÃæ½â¾ö²»Ò»ÖÂÐÔ¡£ÁíÒ»ÖÖ·½·¨¡ª¡ªÊ¹ÓÃÄäÃû»¯¶à»ú¹¹Êý¾Ý½øÐа²È«¼¯ÖÐѵÁ·¡ª¡ª¿ÉÔÚͨ¹ý±ê×¼»¯Ô¤´¦ÀíºÍÖÊÁ¿±£Ö¤¸ÄÉÆÒ»ÖÂÐÔµÄͬʱ±£³ÖÒþ˽¡£½üÆÚ»¹Ìá³öÁË¡°Áª°îÓòÊÊÓ¦¡±£¬¼´ÑµÁ·Ò»¸öͨÓÃÄ£ÐͲ¢¸¨ÒÔ¸üרҵ»¯µÄÓòµ÷ÓÅ˽ÓÐÄ£ÐÍ£¬ËüÃÇÏ໥½»»¥ÒÔ´ï³É¹²Í¬Êä³ö¡£AIÔÚÉñ¾·ÅÉäѧÖеĸºÔðÈÎÍƽø»¹ÐèÒª¸üÇ¿ÓÐÁ¦µÄ¼à¹ÜºÍÔËÓª¿ò¼Ü¡£HIPAAºÍGDPRµÈÏÖÐз¨ÂÉÌṩÁË»ù´¡Ö¸µ¼£¬µ«Î´Õë¶ÔAIÌØÓÐÌôÕ½½øÐж¨ÖÆ£¬ÌرðÊÇÄ£ÐÍÖØѵÁ·¡¢¿É½âÊÍÐÔºÍÊý¾ÝËÝÔ´¡£ÕâЩ¼à¹Ü·¾¶Í¨³£ÓÅÏÈ¿¼ÂǾ²Ì¬ÑéÖ¤£º²¿ÊðÇ°¶Ô¹Ì¶¨Ä£ÐͽøÐе¥´ÎÆÀ¹À£¬¶øδ¿¼ÂDz¿Êðºó¸üпÉÄܵ¼ÖµÄÐÔÄܱ仯¡£ÕâÒ»¾ÖÏÞ¶Ô²¿Êðºó³ÖÐøѧϰµÄ×ÔÊÊӦģÐÍÓÈΪÖØÒª£¬ÒòΪ³ÖÐø¸üпÉÄÜÎÞ·¨ÔÚ²»Öظ´ÉóÅúÁ÷³ÌµÄÇé¿öÏÂÇáÒ×±»ÈÝÄÉ¡£ÐèÒª¹ú¼ÊºÏ×÷À´Öƶ¨ÃæÏòAIµÄÊý¾ÝÖÎÀíÖ¸ÄϺÍÂ×Àí±ê×¼£¬È·±£»¼Õß°²È«ºÍ»¥²Ù×÷ÐÔ¡£´ËÍ⣬¾¼Ã·ÖÎö¡ª¡ª°üÀ¨Ä£ÐÍѵÁ·¡¢»ù´¡ÉèÊ©ºÍÁÙ´²ÕûºÏ³É±¾¡ª¡ªÓ¦ÎªÕþ²ßºÍ²ÉÄɲßÂÔÌṩÐÅÏ¢¡£×ÝÏò¶àÖÐÐÄÑо¿ÆÀ¹Àʱ¼äЧÂÊ¡¢¿ÉÀ©Õ¹ÐԺͳ¤ÆÚ»¼Õß½á¾Ö¶ÔÓÚÔÚÏÖʵ»·¾³ÖÐÑéÖ¤ÕâЩ¹¤¾ßÖÁ¹ØÖØÒª¡£Ëæ×ÅÁÙ´²Ò½Ê¦¶ÔAIÊìϤ¶ÈµÄÌá¸ß£¬Åàѵ¼Æ»®ºÍ»ú¹¹Ö§³Ö½«È·±£×¼È·½â¶Á²¢¼õÉÙÎóÓá£ËæןßÐÔÄÜAIÄ£ÐÍÈÕÒæÈÚÈëÁÙ´²¹¤×÷Á÷³Ì£¬·ÅÉä¿ÆҽʦµÄ½ÇÉ«¿ÉÄÜ´ÓÖ÷ҪͼÏñ½â¶ÁÕßת±äΪ¸ü¾ß¼à¶½ÐÔµÄλÖ㬳䵱Ëã·¨Êä³öµÄÑéÖ¤Õß¡£\n7 ½áÂÛ\nAIÒѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧµÄ¸ñ¾Ö£¬ÔÚÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌЧÂʺÍÁÙ´²¾ö²ßÖ§³Ö£¨CDS£©·½ÃæÌṩÁËÇ°ËùδÓеĽøÕ¹¡£CNN¡¢U-Net±äÌåºÍÐÂÐË»ù´¡Ä£Ð͵ÈDL¼Ü¹¹ÔÚ¶àÖÖÓ°ÏñÈÎÎñÖÐÕ¹ÏÖ³ö׿ԽÐÔÄÜ£¬°üÀ¨²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºó·ÖÎö¡£È»¶ø£¬°éËæÕâЩ¼¼ÊõÊÕÒæ¶øÀ´µÄÊǸ´ÔÓµÄÂ×Àí¡¢¼à¹ÜºÍʵ¼ùÌôÕ½¡£Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼û¡¢¿É½âÊÍÐԺͲ»¹«Æ½»ñÈ¡µÈÎÊÌâ±ØÐëÔڹ㷺ÁÙ´²ÕûºÏ֮ǰµÃµ½½â¾ö¡£ÎȽ¡µÄÖÎÀí¿ò¼Ü¡¢Í¸Ã÷µÄÑéÖ¤ºÍ°üÈÝÐÔµÄÊý¾Ý¼¯´ú±íÐÔ¶ÔÓÚÈ·±£AIϵͳ°²È«¹«Æ½µØ·þÎñ»¼ÕßÖÁ¹ØÖØÒª¡£ÁÙ´²Ò½Ê¦¡¢Ñо¿ÈËÔ±¡¢¹¤³ÌʦºÍÕþ²ßÖƶ¨ÕßÖ®¼äµÄ³ÖÐøÐ×÷¶ÔÓÚÃֺϴ´ÐÂÓ븺ÔðÈÎʵʩ֮¼äµÄ²î¾àÖÁ¹ØÖØÒª¡£Ëæ×ÅÁìÓò³ÉÊ죬ÖصãÓ¦´Ó¸ÅÄîÑé֤׼ȷÐÔתÏò¿É½âÊÍÐÔ¡¢·º»¯ÐÔºÍÂ×Àí¹ÜÀí¡£Í¨¹ý³ÖÐøµÄ¿çѧ¿ÆºÏ×÷ºÍ¼à¶½£¬AIÔÚÉñ¾Ó°ÏñѧÖв»½öÓÐÍûÌá¸ßÕï¶Ï¾«¶È£¬»¹ÓÐÍûÒÔ¹«Æ½¿ÉÐŵķ½Ê½ÖØж¨ÒåÉñ¾»¤Àí±ê×¼¡£","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 14247 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 14247 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":14247,"summary_length":5898,"usable_text_length":14247,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":14247,"summary_length":5898}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 14247 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":14247,"summary_length":5898,"usable_text_length":14247,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":14247,"summary_length":5898}},"actions":{"read":"/item/90989","export_markdown":"/api/items/90989/export?format=markdown","export_json":"/api/items/90989/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-9/20260927000425378.htm"}},"digest":{"id":90989,"title":"人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","source":"生物通","topic":"ai","published_at":"2026-09-27T01:00:54+00:00","excerpt":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations ±à¼ÍƼö£º ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning,…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 14247 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量 - 生物通","subtitle":"生物通 · 2026-09-27","summary":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations ±à¼ÍƼö£º ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine…","badges":["quality:high"],"links":{"read":"/item/90989","original":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-9/20260927000425378.htm"},"quality_warning":null},"export":{"title":"人工智能在神经影像学中的应用：多中心性能、临床结局与伦理考量 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","summary":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs.","source":"生物通","date":"2026-09-27T01:00:54+00:00","content":"¡¶Clinical Neuroimaging¡·£ºArtificial Intelligence in Neuroimaging: Multicenter Performance, Clinical Outcomes, and Ethical Considerations\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convol\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n±³¾°£ºÈ˹¤ÖÇÄÜ£¨Artificial Intelligence, AI£©ºÍ»úÆ÷ѧϰ£¨Machine Learning, ML£©Òѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧÁìÓò£¬ÎªÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌÓÅ»¯ºÍÔ¤²â½¨Ä£ÌṩÁËȫй¤¾ß¡£Éî¶Èѧϰ¼Ü¹¹µÄ×îнøÕ¹£¬°üÀ¨¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©¡¢U-Net±äÌå¼°»ù´¡Ä£ÐÍ£¨Foundation Models£©£¬ÔÚ²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºóÅжϷ½ÃæÈ¡µÃÁËÏÔÖøÐÔÄÜ¡£È»¶ø£¬¶àÖÐÐÄÑéÖ¤¡¢Â×ÀíÖÎÀíºÍ¹«Æ½·º»¯ÐÔ·½ÃæµÄÌôÕ½ÈÔÊǹ㷺ÁÙ´²²ÉÄɵÄÖ÷ÒªÕÏ°¡£\n·½·¨£ºÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö¡£Ñо¿ÒÀ¾ÝÆä¶Ô¶àÖÐÐÄÊý¾Ý¡¢¿ç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨Federated Learning, FL£©¿ò¼ÜµÄ²àÖؽøÐÐÑ¡ÔñÐÔÄÉÈ룬ÒÔÓÅÏÈ»ñÈ¡¿ç»ú¹¹·º»¯ÐÔµÄÖ¤¾Ý£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£\n½á¹û£ºAIËã·¨ÔÚ¶àÖÖÓ°Ïñģ̬ÖÐÕ¹ÏÖ³ö½Ï¸ßµÄÕï¶Ï׼ȷÐÔ£¬»ùÓÚCNNµÄÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖÐDiceÏàËÆϵÊý£¨Dice Similarity Coefficient, DSC£©´ïµ½0.79¨C0.90£¬ÔÚÂÄÚ³öѪ¼ì²âÖÐÇúÏßÏÂÃæ»ý£¨Area Under the Curve, AUC£©Öµ³¬¹ý0.98¡£Áª°îѧϰ·½·¨ÔÚ²»Ëðº¦Êý¾ÝÒþ˽µÄÇ°ÌáϸÄÉÆÁËÄ£ÐÍ·º»¯ÐÔ¡£È»¶ø£¬Êý¾ÝÒìÖÊÐÔ¡¢¿É½âÊÍÐÔÓÐÏÞÒÔ¼°È±·¦±ê×¼»¯ÑéÖ¤¿ò¼ÜµÈÎÊÌâÈÔÈ»´æÔÚ¡£\nÂ×Àí¿¼Á¿£ºÖ÷ÒªÂ×ÀíÌôÕ½Éæ¼°Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼ûÒÔ¼°Å¼È»·¢ÏֵĴ¦Öá£ÏÖÐмà¹Ü¿ò¼Ü£¨°üÀ¨Í¨ÓÃÊý¾Ý±£»¤ÌõÀý£¨General Data Protection Regulation, GDPR£©ºÍ½¡¿µ±£ÏÕЯ´øÓëÔðÈη¨°¸£¨Health Insurance Portability and Accountability Act, HIPAA£©£©Î´Äܳä·ÖÓ¦¶ÔAIÌØÓеÄÎÊÌ⣬ؽÐèÖƶ¨ÊÊÓ¦ÐÔ¡¢Í¸Ã÷ÇÒÈ«Çòе÷Ò»ÖµÄÖÎÀíÌåϵ¡£\n½áÂÛ£ºAIÔÚÉñ¾Ó°ÏñѧÖоßÓÐÌáÉýÕï¶Ï¾«¶ÈºÍÁÙ´²Ð§Âʵľ޴óDZÁ¦¡£Îª³ä·Ö·¢»ÓÆäÈ«²¿¼ÛÖµ£¬¶àÖÐÐÄÐ×÷¡¢¿É½âÊÍÈ˹¤ÖÇÄÜ£¨Explainable AI, XAI£©ºÍÇ¿ÓÐÁ¦µÄÂ×Àí¼à¶½¶ÔÓÚÈ·±£Æ乫ƽ¡¢¿ÉÐŵØÈÚÈëÁÙ´²Êµ¼ùÖÁ¹ØÖØÒª¡£\nÂÛÎÄÖ÷ÌåÄÚÈÝ×ܽá\n1 ÒýÑÔ\nÈ˹¤ÖÇÄÜÕýÔÚѸËٸıäҽѧ¶à¸öÁìÓò£¬ÓÈÆäÔÚÉñ¾Íâ¿ÆºÍÉñ¾Ó°ÏñѧÖУ¬Õï¶Ï¾«¶ÈÖÁ¹ØÖØÒª¡£½üÄêÀ´£¬¾í»ýÉñ¾ÍøÂ磨Convolutional Neural Networks, CNNs£©ºÍ×ÔÅäÖÃnnU-Net¿ò¼ÜµÈ×ÔѧϰģÐÍÒѱ»¹ã·º²ÉÓã¬ÔÚʶ±ðÉñ¾ÏµÍ³Òì³£·½ÃæÕ¹ÏÖ³ö׿ԽÐÔÄÜ¡£×î½ü£¬Transformer¼Ü¹¹ºÍ»ù´¡Ä£ÐÍ¡ª¡ªÔÚ´ó¹æÄ£ºÍÒìÖÊÐÔÊý¾Ý¼¯ÉÏԤѵÁ·µÄ´ó¹æÄ£Ëã·¨¡ª¡ªÒѳÉΪ·ÖÎö¸´ÔÓÉñ¾Ó°ÏñÊý¾ÝµÄÓÐÁ¦¹¤¾ß¡£È»¶ø£¬Ò»¸ö¹Ø¼üÌôÕ½ÔÚÓÚÈ·±£AIÄ£ÐÍÔÚ²»Í¬Ò½Ôº¡¢É¨ÃèÒǺͻ¼ÕßȺÌå¼ä±£³ÖÒ»ÖµÄÐÔÄÜ£¬ÕâÒ»ÎÊÌâ³£±»³ÆΪ¡°ÓòÆ«ÒÆ¡±£¨Domain Shift£©£¬¿ÉÄÜÏÔÖø½µµÍÄ£ÐÍÔÚÔʼѵÁ·»·¾³Ö®ÍâÓ¦ÓÃʱµÄ׼ȷÐÔ¡£¶àÖÐÐÄÑо¿Í¨¹ýÀûÓöà¸öÖÐÐĺÍÐÒéÊÕ¼¯µÄÊý¾ÝÑéÖ¤AIϵͳ£¬´Ó¶ø¸ÄÉÆ·º»¯ÐÔºÍÁÙ´²¿É¿¿ÐÔ¡£Áª°îѧϰ£¨Federated Learning, FL£©Ê¹¸÷»ú¹¹Äܹ»ÔÚÎÞÐè½»»»»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·AIËã·¨£¬ÔÚ±£»¤Òþ˽µÄͬʱÔöÇ¿Ä£ÐÍÎȽ¡ÐÔ¡£¾¡¹ÜÈç´Ë£¬ÕâЩ¼¼Êõ±ØÐëÔÚÑϸñµÄ¼à¹ÜºÍÂ×Àí¿ò¼ÜÄÚÔËÐУ¬ÒòΪ´ó¹æÄ£Ó°ÏñÊý¾Ý¼¯Èô±£»¤²»µ±ÈÔÃæÁÙÀÄÓûòй¶·çÏÕ¡£\n2 ·½·¨Ñ§\nÑо¿ÈËԱͨ¹ýPubMedºÍGoogle Scholar£¨2015¨C2025Ä꣩¿ªÕ¹ÁËÒ»ÏîÕë¶ÔÐÔÐðÊöÐÔ×ÛÊö£¬Ö¼ÔÚʶ±ðÒÔ¶àÖÐÐÄÑé֤ΪÖصãµÄAIÉñ¾Ó°ÏñѧÑо¿¡£¼øÓÚ¸ÃÁìÓòµÄ¿ìËÙÀ©Õ¹ºÍÒìÖÊÐÔ£¬±¾×ÛÊöÓÅÏÈÄÉÈëչʾ¿ç»ú¹¹·º»¯ÐÔµÄÑо¿£¬¶ø·Ç¶ÔËùÓÐAIÓ¦ÓýøÐÐÏ꾡±àÄ¿¡£Ñо¿»ùÓÚÔ¤Ïȶ¨ÒåµÄ±ê×¼½øÐÐÑ¡ÔñÐÔÄÉÈ룬Öصã¹Ø×¢¶àÖÐÐÄÊý¾ÝʹÓᢿç»ú¹¹ÍⲿÑéÖ¤»òÁª°îѧϰ£¨FL£©¿ò¼Ü¡£¼ìË÷²ÉÓò¼¶ûÔËËã·û½áºÏÊÜ¿Ø´Ê»ãºÍ×ÔÓÉÎı¾ÊõÓʹÓÃÁËÈý×é¼ìË÷ʽ¡£¹²36ƪÂÛÎÄ·ûºÏÄÉÈë±ê×¼£¬°üÀ¨8ÏîÔʼÑо¿¡¢19ƪÐðÊöÐÔ×ÛÊö¡¢4ƪϵͳ×ÛÊö¡¢3ƪÕþ²ß¸ÅÄîÂÛÎÄ¡¢1ƪ·½·¨Ñ§Ñо¿ºÍ1ƪÊý¾Ý¼¯ÂÛÎÄ¡£Åųý±ê×¼°üÀ¨£º·ÇÓ¢ÎÄ·¢±íµÄÑо¿¡¢²»Éæ¼°AIÔÚÉñ¾Ó°ÏñѧÖÐÓ¦ÓõÄÑо¿¡¢È±·¦³ä·Ö·½·¨Ñ§»ò½á¹ûÐÅÏ¢µÄ»áÒéÕªÒª£¬ÒÔ¼°È±·¦ÊµÖ¤»òϵͳ֤¾ÝµÄ¹ÛµãÎÄÕ¡¢ÆÀÂÛ»òÉçÂÛ¡£\n3 ½á¹û\n3.1 Éñ¾·ÅÉäѧÖеĵ±Ç°AIËã·¨\nÉñ¾Ó°ÏñѧÊÇÒ»¸ö¿ìËÙ·¢Õ¹µÄÁìÓò£¬²ÉÓÃMRIºÍCTµÈ·ÇÇÖÈëÐÔģ̬À´¿ÉÊÓ»¯ºÍÑо¿ÈËÄԵĽṹÓ빦ÄÜ¡£¹ýȥʮÄêÖУ¬¼¼ÊõºÍ¼ÆËã½ø²½ÒѸıäÁËÕâһѧ¿Æ£¬Ìá¸ßÁËÕï¶Ï¹¤×÷Á÷³ÌµÄ¾«¶È¡¢ËٶȺͿÉÖظ´ÐÔ¡£AIÒѳÉΪÏÖ´úÉñ¾·ÅÉäѧµÄ»ùʯ£¬ÎªÍ¼Ïñ½â¶Á¡¢¼²²¡¼ì²âºÍÔ¤ºóÅжÏÌṩÁËз½·¨¡£\n3.2 ¾µäÓëÉî¶Èѧϰ£¨Deep Learning, DL£©·½·¨\n¾µä»úÆ÷ѧϰ£¨classical Machine Learning, cML£©ÊÇAIµÄÔçÆÚÐÎʽ£¬Ëã·¨´Ó½á¹¹»¯Êý¾ÝÖÐʶ±ðģʽ²¢Í¨¹ýµü´úѵÁ·µ÷Õû²ÎÊý¡£ÈýÖÖÖ÷Ҫѧϰ·¶Ê½°üÀ¨¼à¶½Ñ§Ï°¡¢Î޼ලѧϰºÍ°ë¼à¶½Ñ§Ï°¡£ÔÚcML»ù´¡ÉÏ£¬DLÀûÓöà²ãÈ˹¤Éñ¾ÍøÂçѧϰͼÏñµÄ·Ö²ãÌØÕ÷¡£ÆäÖУ¬CNNÊÇ´¦ÀíÉñ¾Ó°ÏñÊý¾ÝµÄÖ÷µ¼¼Ü¹¹¡£»ùÓÚCNNµÄ¿ò¼ÜÈçU-Net¼°ÆäÓÅ»¯±äÌånnU-NetÔÚ²¡Ôî·Ö¸îºÍÄÔÖ×Áö¹´»·½ÃæÒÑ´ïµ½×îÏȽøÐÔÄÜ¡£U-Net¼Ü¹¹ÕûºÏÁ˱àÂëÆ÷¡ª½âÂëÆ÷½á¹¹£¬ÌáÈ¡¹Ø¼üͼÏñÌØÕ÷²¢Öؽ¨ÏàÓ¦´óСµÄ·Ö¸îͼ£¬¶ønnU-NetÄÜ×ÔÖ÷ÊÊÓ¦Êý¾Ý¼¯Ìض¨ÌØÕ÷½øÐÐÅäÖÃÓÅ»¯£¬ÔÚ¶àģ̬MRI·ÖÎöÖвúÉú¸üÓŵķָ¶È¡£\n3.3 Áª°îÓë¶àÖÐÐÄѧϰ¿ò¼Ü\n´«Í³DLÄ£Ð͵ÄÖ÷Òª¾ÖÏÞÔÚÓÚÒÀÀµ¼¯ÖÐʽÊý¾Ý¼¯£¬ÕâÒý·¢Òþ˽µ£ÓDz¢ÏÞÖÆÁËÊý¾Ý¶àÑùÐÔ¡£FL×÷ΪһÖÖ·¶Ê½£¬ÔÊÐí¶à¸ö»ú¹¹ÔÚ²»½»»»Ôʼ»¼ÕßÊý¾ÝµÄÇé¿öÏÂÐ×÷ѵÁ·¹²ÏíÄ£ÐÍ¡£Ä£ÐͲÎÊýÔÚÖÐÐĽøÐоۺϺóÖØзַ¢¸ø¸÷Õ¾µã½øÐеü´úÓÅ»¯¡£FL¿ÉʵʩΪˮƽ£¨Í¬ÖÊ£©Ñ§Ï°¡ª¡ª²»Í¬Õ¾µãµÄÊý¾Ý¼¯¹²ÏíÏàͬÌØÕ÷¿Õ¼ä£¬»ò´¹Ö±£¨ÒìÖÊ£©Ñ§Ï°¡ª¡ª¸÷Õ¾µãΪÖصþ»¼Õ߶ÓÁй±Ï×»¥²¹ÌØÕ÷¡£ÕâЩȥÖÐÐÄ»¯¿ò¼ÜÄܹ»ÊµÏÖ´ó¹æÄ£¡¢±£»¤Òþ˽µÄÄ£ÐÍ¿ª·¢£¬²¢¸ÄÉÆ¿çɨÃèÒǺÍÈËȺµÄ·º»¯ÐÔ¡£\n3.4 Éñ¾·ÅÉäѧÖеÄÁÙ´²Ó¦ÓÃ\nAIËã·¨ÔÚ¶à¸öÉñ¾Ó°ÏñÁìÓòÕ¹ÏÖ³öÇ¿´óµÄÕï¶ÏÐÔÄÜ¡£ÀýÈ磬½áºÏ¶àÐòÁÐMRIµÄCNNÄ£ÐÍÔÚÄÔÖ×Áö·Ö¸îÖдﵽ½Ó½üר¼ÒµÄ׼ȷÐÔ£¬AUCֵΪ0.98¡À0.04£¬ÁéÃô¶È94%£¬ÌØÒì¶È97%£¬DSCԼΪ0.79¡À0.12¡£ÔÚ¼±ÕïÉñ¾·ÅÉäѧÖУ¬AIϵͳ¸¨Öú¼±ÐÔ²¡ÀíµÄ¼ì²âºÍ·ÖÕÈçȱѪÐÔ×äÖС¢ÂÄÚ³öѪ¡¢¶¯ÂöÁöºÍ¶¯¾²Âö»ûÐΡ£DLËã·¨ÔÚ·ÇÔöÇ¿CTÉϵÄÔçÆÚ×äÖмì²âÖÐÓÅÓÚ·ÅÉä¿Æҽʦ£¨AI 37.3% vs. ·ÅÉä¿Æҽʦ33.3%£©£¬×÷Ϊ¸¨Öú¹¤¾ßʱÁéÃô¶ÈÏÔÖøÌá¸ß£¨Ê¹ÓÃAI 41.3% vs. ²»Ê¹ÓÃ33.3%£©¡£AIÔÚÂÄÚ³öѪ¼ì²â·½ÃæҲȡµÃÁ˸߾«¶È£¬»ùÓÚ25,000ÓàÀýCTɨÃèѵÁ·µÄ´ó¹æģģÐÍÔÚ³öѪÑÇÐÍ·ÖÀàÖÐAUC³¬¹ý0.98¡£\n3.5 ÆÀ¼ÛÖ¸±ê\nAIÄ£ÐÍÔÚÉñ¾·ÅÉäѧÖеÄÐÔÄÜͨ³£Ê¹Óñê×¼Ö¸±êÁ¿»¯¡£DSCºâÁ¿Ô¤²â·Ö¸îÓëÕæʵ·Ö¸îÖ®¼äµÄÖصþ£¬·¶Î§´Ó0£¨ÎÞÖصþ£©µ½1£¨ÍêÈ«Ò»Ö£©¡£¶ÔÓÚ·ÖÀàÈÎÎñ£¬Õï¶Ï׼ȷÐÔͨ¹ýÁéÃô¶È¡¢ÌØÒì¶È¡¢ÑôÐÔºÍÒõÐÔÔ¤²âÖµÒÔ¼°ÊÜÊÔÕß¹¤×÷ÌØÕ÷ÇúÏßÏÂÃæ»ý£¨AUC£©±¨¸æ£¬½Ó½ü1µÄÖµ±íʾÓÅÒìµÄÅбðÐÔÄÜ¡£\n4 AIÔÚÉñ¾Ó°ÏñѧÖеĽá¾Ö\n4.1 Õï¶ÏÐÔÄÜÓë׼ȷÐÔ\nBeliveauµÈÈËÆÀ¹ÀÁ˶àÖÖCNN¼Ü¹¹ÔÚ´ÅÃô¸Ð¼ÓȨ³ÉÏñ£¨Susceptibility-Weighted Imaging, SWI£©Éϱê¼ÇÉÄÔºËÍŵıíÏÖ£¬CNNÔÚÄÚ²¿Êý¾Ý¼¯ÉÏ´ïµ½DSC 0.85¨C0.90£¬ÔÚÍⲿÊý¾ÝÉϱ£³ÖÇ¿·º»¯ÐÔ£¨Dice¡Ö0.83£©£¬ÓÅÓڲο¼Ä£ÐÍ£¨Dice¡Ö0.77£©¡£ÔÚÖ×ÁöÓ¦ÓÃÖУ¬Ò»Ïî±È½ÏcMLºÍDLËã·¨µÄϵͳ×ÛÊö·¢ÏÖ£¬DLÄ£ÐÍÔÚÄÔתÒÆÁö£¨Brain Metastasis, BM£©¼ì²âÖдﵽ¸ü¸ßµÄÕï¶ÏÁéÃô¶È£¬ºÏ²¢¿É¼ì²âÂÊΪ90%£¬Ã¿Àý»¼ÕߵļÙÑôÐÔÂÊÏÔÖøµÍÓÚcML·½·¨£¨10 vs. 135, p<0.001£©¡£RauscheckerµÈÈËÆÀ¹ÀÁ˽áºÏDLºÍ±´Ò¶Ë¹ÍøÂçµÄMRI¼ø±ðÕï¶ÏAIϵͳ£¬Ëã·¨´ïµ½91%µÄÇ°ÈýλÕï¶Ï׼ȷÂÊ£¬±íÏÖÓëѧÊõÉñ¾·ÅÉä¿ÆҽʦÏ൱£¨86%; p=0.20£©£¬ÓÅÓÚסԺҽʦ£¨56%; p<0.001£©¡¢½øÐÞҽʦ£¨77%; p=0.003£©ºÍÆÕͨ·ÅÉä¿Æҽʦ£¨57%; p<0.001£©¡£\n4.2 ÁÙ´²ÊµÊ©Ó빤×÷Á÷³ÌÓ°Ïì\nÔÚ¼±ÐÔÉñ¾Ó°ÏñѧÖУ¬»ùÓÚCNNµÄÄ£ÐÍÔÚ´óѪ¹Ü±ÕÈû£¨Large Vessel Occlusion, LVO£©×äÖмì²âÖдﵽ85%µÄÁéÃô¶È£¬ÏÔÖøÓÅÓÚËæ»úÉÁÖÄ£ÐÍ£¨68%£©£¬²¢¾ßÓмÓËÙ·ÖÕïºÍÖÎÁÆʱ¼äÏßµÄDZÁ¦¡£RAPID ICH¡¢Viz.aiºÍAldoc MedicalµÈ¹¤¾ßÀûÓÃDL×Ô¶¯Ê¶±ðºÍ·ÖÀàCTÉϵijöѪ£¬×÷ΪʵʱÕï¶Ï¸¨Öú£¬Ìṩ¡°¶þ´ÎÔĶÁ¡±¡¢ÐÖúÖÊÁ¿±£Ö¤²¢°ïÖú·ÅÉä¿ÆҽʦÓÅÏÈ´¦Àí½ô¼±²¡Àý£¬¿ÉÄܼõÉÙÅжÁÑÓ³Ù¡£\n4.3 ÕæʵÊÀ½ç²ÉÓÃÓëÓû§ÈÏÖª\nº«¹ú·ÅÉä¿Æҽʦȫ¹úµ÷²éÏÔʾ£¬60.3%£¨223/370£©Òѽ«»ùÓÚAIµÄÈí¼þÄÉÈëʵ¼ù£¬Ö÷ÒªÓÃÓÚ²¡Ôî¼ì²â£¨82.1%£©¡¢Õï¶Ï¸¨Öú£¨55.2%£©ºÍͼÏñ·ÖÀࣨ55.2%£©¡£67.6%µÄÊÜ·ÃÕß×¢Òâµ½»¼Õß¹ÜÀíµÄ¸ÄÉÆ£¬85.1%¶ÔAIÐÔÄܱíʾ×ÜÌåÂúÒ⡣Ȼ¶ø£¬92%µÄÊÜ·ÃÕßÈÏΪÐèÒªÕý¹æ½ÌÓýºÍÖ¸ÄÏÒÔÈ·±£AIÊä³öµÄÊʵ±Ê¹Óúͽâ¶Á¡£\n4.4 ÁÙ´²½á¾Ö×ܽá\nÔÚ¶à¸öÁìÓò£¬AIÇý¶¯µÄÉñ¾Ó°ÏñϵͳչÏÖ³ö¸ßÕï¶Ï׼ȷÐÔ¡¢Ð§ÂʺͿÉÀ©Õ¹ÐÔ£¬ÐÔÄܳ£Óëר¼ÒÉñ¾·ÅÉä¿ÆҽʦÏ൱¡£ÆäÁÙ´²ÕûºÏÌṩÁ˼ò»¯¹¤×÷Á÷³Ì¡¢Ö§³Ö¾ö²ßºÍ¸ÄÉÆ»¼Õß½á¾ÖµÄ»ú»á¡£È»¶ø£¬ÕâЩÒæ´¦ÒÀÀµÓÚÑϸñµÄ¶àÖÐÐÄÑéÖ¤ÒÔ¼°¶Ô¿É½âÊÍÐÔ¡¢ÁÙ´²Ò½Ê¦½ÌÓýºÍÂ×ÀíÖÎÀíµÄ³ÖÐø¹Ø×¢¡£\n5 Â×Àí¿¼Á¿Óë¾ÖÏÞÐÔ\n5.1 Êý¾ÝÒþ˽ÓëÖÎÀí\nÊý¾ÝÒþ˽ÊÇAIÇý¶¯Éñ¾Ó°ÏñÖÐ×î½ôÆȵÄÂ×Àí¹ØÇÐÖ®Ò»£¬ÓÈÆäÊǵ±´óÐÍÓ°ÏñÊý¾Ý¼¯´æ´¢ÔÚ¿ç¹ú¼Ê±ß½ç¾ÛºÏÐÅÏ¢µÄÃÅ»§»òÔÆϵͳÖÐʱ¡£ÄÔ²¿É¨Ãè¾ßÓжÀÌØ·çÏÕ£¬ÒòΪ½âÆʽṹ¿ÉÓë¸öÈËÊý¾ÝÆ¥Åä´Ó¶øʵÏÖÔÙʶ±ð¡£Å·ÃËͨÓÃÊý¾Ý±£»¤ÌõÀý£¨GDPR£©Çø·Ö¸öÈËÊý¾Ý¡¢È¥±êʶ»¯Êý¾ÝºÍÍêÈ«ÄäÃûÊý¾Ý£¬¶øÖйú¸öÈËÐÅÏ¢±£»¤·¨£¨PIPL£©½«ÉúÎïʶ±ðºÍÒ½ÁÆÐÅÏ¢¹éÀàΪ¸ß¶ÈÃô¸ÐÊý¾Ý¡£È»¶ø£¬¹ú¼ÒºÍ»ú¹¹¼äÒþ˽·¨ÂɵÄÒìÖÊÐÔʹ¿ç¾³Êý¾Ý¹²Ïí¸´ÔÓ»¯¡£Áª°îѧϰ£¨FL£©Äܹ»ÔÚÎÞÐè´«ÊäÔʼÊý¾ÝµÄÇé¿öϽøÐпç»ú¹¹Ä£ÐÍѵÁ·£¬¼õÉÙ¼¯Öд洢¿âµÄÐèÇó¡£Êý¾ÝʹÓÃÐÒ飨Data Use Agreements, DUAs£©ºÍÊý¾Ý´«ÊäÐÒ飨Data Transfer Agreements, DTAs£©µÈÕýʽÐÒ鶨ÒåÁËÔðÈβ¢·ÀÖ¹ÀÄÓá£\n5.2 żȻ·¢ÏÖÓë¿É½âÊÍÐÔ\nżȻ·¢ÏֵĹÜÀí¡ª¡ªÑо¿»òÕï¶ÏÓ°ÏñÖз¢ÏÖµÄÒâÍâÒì³£¡ª¡ªÌá³öÁËÁíÒ»Â×ÀíÀ§¾³¡£AIϵͳÒò¸ßÁéÃô¶ÈºÍÐí¶àDLÄ£Ð͵ġ°ºÚÏ䡱ÌØÐÔ¶ø¼Ó¾çÁËÕâÒ»ÎÊÌ⣬ÏÞÖÆÁËÁÙ´²Ò½Ê¦½â¶ÁËã·¨ÍÆÀíµÄÄÜÁ¦¡£AIϵͳµÄ¿ª·¢ÕßÓ¦·ÅÆúÓÅÏÈ¿¼ÂÇÉÌÒµÃØÃܶø·Ç͸Ã÷ÐԵġ°ÒþÐοÆѧ¡±×ö·¨¡£¿ª·¢Õß±ØÐëÈ·±£³ÖÐø¼à²âºÍƵ·±ÓÅ»¯AIϵͳ£¬ÒÔ¸úÉϲ»¶Ï·¢Õ¹µÄÁÙ´²Êµ¼ù¡£ÁÙ´²Ò½Ê¦ÔÚ½«ÕâЩ¹¤¾ßÕûºÏµ½ÁÙ´²Êµ¼ùÖÐʱÐèÒª²Éȡƽºâ·½·¨£¬Í¬Ê±²»Ëðº¦ÆäÁÙ´²Åжϡ£½«Î±Ó°»òÕý³£±äÒìÎóʶ±ðΪ²¡Àí¿Éµ¼Ö»¼Õß½¹ÂÇ¡¢²»±ØÒªµÄËæ·Ã¼ì²é»òÎóÕï¡£¸÷˾·¨¹ÜϽÇø¼à¹Ü¿ò¼ÜµÄ²»Ò»ÖÂÐÔʹµÃ½¨Á¢±ê×¼»¯³ÌÐòÀ´¹ÜÀíÕâЩ·¢ÏÖ±äµÃÀ§ÄÑ¡£\n5.3 Ë㷨ƫ¼ûÓ빫ƽÐÔ\nË㷨ƫ¼ûÊÇAIÔÚÉñ¾Ó°ÏñÖÐÂ×ÀíÓ¦Óõĸù±¾¾ÖÏÞ¡£Ò»Ïî½üÆÚÜöÝÍ·ÖÎö·¢ÏÖ£¬97.5%µÄѵÁ·Êý¾Ý¼¯À´×Ô¸ßÊÕÈë»òÖиßÊÕÈëµØÇø£¬µ¼ÖÂϵͳÐÔȱ·¦¶àÑùÐÔ£¬Ï÷ÈõÁËÈ«ÇòÊÊÓÃÐÔ¡£Ò»ÏîAIÕï¶Ï°¢¶û´Äº£Ä¬²¡µÄÑо¿ËµÃ÷ÁËÕâһЧӦ£ºÔÚÃÀ¹ú°¢¶û´Äº£Ä¬²¡Éñ¾Ó°Ïñѧ³«Ò飨Alzheimer's Disease Neuroimaging Initiative, ADNI£©Êý¾Ý¼¯ÉÏѵÁ·µÄCNNÔÚ°Ä´óÀûÑÇAIBL¶ÓÁÐÖбíÏÖÁ¼ºÃ£¬µ«ÔÚÒâ´óÀûI-ADNIÊý¾Ý¼¯ÉÏÏÔÖø¶ñ»¯£¬×¼È·ÂʽöΪ78%¡£Ðí¶àÓÃÓÚAI¿ª·¢µÄ»ùÓÚ»úÆ÷ѧϰ£¨Machine Learning, ML£©µÄÊý¾Ý¿âÀ´×Ô¸ßÊÕÈë¹ú¼Ò£¨Å·Ö޺ͱ±ÃÀ£©£¬¶ÔÑÇÖÞ¡¢À¶¡ÃÀÖ޺ͷÇÖÞÈËȺµÄÄÉÈëÓÐÏÞ£¬Ôì³É¡°Ã÷È·µÄselection bias¡±¡£Ó¦Öƶ¨Õþ²ßÇ¿ÖÆÄÉÈëÖÖ×å¡¢Ãñ×å¡¢ÄêÁä¡¢ÐÔ±ðºÍÉç»á¾¼ÃµØλµÈÈË¿Úͳ¼Æѧ±äÁ¿ÒÔ½øÐÐÆ«¼ûÉó¼Æ¡£Ó¦²ÉÓÃFUTURE-AIÖ¸ÄϵÈÂ×Àí×¼Ôò£¬È·±£¹«Æ½ÐÔºÍÆÕ±éÐÔÔÔòÈÚÈ뿪·¢¹ý³Ì¡£ÃÀ¹ú¡°All of Us¡±Ñо¿¼Æ»®µÈ¿É×÷Ϊ³¬Ô½µØÀíºÍÉç»á¾¼Ã±ß½ç´´½¨È«ÇòÊý¾Ý¿âµÄÄ£ÐÍ¡£\n5.4 ¼à¹ÜÓëʵ¼ù¾ÖÏÞÐÔ\nÏÖÐмà¹Ü»·¾³ÉÐδÊÊÓ¦¶àÖÐÐÄAIÑо¿µÄ¸´ÔÓÐÔ¡£¹ÜÀíÁÙ´²Êý¾Ý¼¯ÊÕ¼¯¡¢Ê¹Óúͽ»»»µÄÉç»á·¨ÂÉ¿ò¼Ü²îÒì×è°Á˹ú¼ÊºÏ×÷¡£´ËÍ⣬Õë¶Ô³ÖÐø´ÓÐÂÊý¾ÝѧϰµÄ×ÔÊÊÓ¦Ëã·¨µÄÉÏÊкó¼à²â»òÑéÖ¤±ê×¼»¯³ÌÐòºÜÉÙ¡£È±·¦È«Ãæ¼à¶½Ê±£¬Â×ÀíºÍ°²È«Ê§Îó¿ÉÄÜÔÚ»¼ÕßÉ˺¦·¢ÉúÇ°²»±»·¢ÏÖ¡£\n5.5 ·¨ÂÉÔðÈÎ\nAI¸¨ÖúÉñ¾Ó°ÏñµÄÁíÒ»¸ö¹ØÇÐÊÇ·¨ÂÉÔðÈΣ¬ÒòΪҽʦ³Ðµ£Õï¶ÏÔðÈΡ£ÔðÈα»ÊÓΪÁÙ´²Ò½Ê¦ÓëË㷨ϵͳ֮¼äµÄ·Ö²¼Ê½¹¹½¨£¬·´Ó³ÁËÁÙ´²Êµ¼ùÖÐÏò¹²Ïí¾ö²ß·¶Ê½µÄת±ä¡£Îª½µµÍ·¨ÂÉ·çÏÕ£¬ÁÙ´²Ò½Ê¦±ØÐëÈ·±£AIµÄʹÓ÷ûºÏͬһר¿ÆºÏ¸ñ´ÓÒµÕߵıê×¼»¤Àíˮƽ¡£·¨ÂÉ·ÖÎö¿¼ÂÇÁ½ÖÖÇéÐΣºÒ»ÊÇҽʦ¾Ü¾øÁË·ûºÏ±ê×¼»¤ÀíµÄÕýÈ·½¨Ò飻¶þÊÇҽʦ×ñÑÁ˲»·ûºÏ±ê×¼»¤ÀíµÄ´íÎóAI½¨Òé¡£Èç¹ûAIÄܳ¬Ô½ÈËÀà¾ö²ßÄÜÁ¦£¬·¨ÂÉר¼ÒÔ¤²â¿ÉÄÜÓбØÒª²ÉÄÉAIÁÙ´²¾ö²ßÖ§³Ö£¨Clinical Decision Support, CDS£©¡£Èç¹ûAI¹¤¾ßµÄʹÓó¬³ö¼à¹ÜÊÚȨ£¨ÈçFDAÐí¿ÉºÍCE±êÖ¾£©Ö¸¶¨µÄÔ¤ÆÚÓÃ;£¬ÔðÈηçÏÕ»áÔö¼Ó£¬Òò´Ë´ÓÒµÕßÓ¦Á˽âÄ¿±êÈËȺºÍÊäÈëÊý¾ÝÒªÇóÒÔ±£³Ö·¨ÂÉÕýµ±ÐÔ¡£\n6 ÌÖÂÛ\n±¾×ÛÊöÇ¿µ÷ÁËAIºÍ»úÆ÷ѧϰ£¨ML£©ÔÚÉñ¾·ÅÉäѧÖеÄÑ¡¶¨½øÕ¹ºÍÁÙ´²Ç±Á¦£¬Ìرð¹Ø×¢¶àÖÐÐÄÑéÖ¤ºÍʵʩ¡£Ëù¿¼²ìµÄ¼Ü¹¹°üÀ¨cML¼°ÆäÑÜÉúDL¡ª¡ªÓÈÆäÊÇU-NetºÍnnU-NetµÈCNN¡ª¡ªÒÔ¼°¸üеÄTransformerºÍ»ù´¡Ä£ÐÍ¡£ÕâЩϵͳÔÚ¶àÖÖÉñ¾Ó°ÏñÓ¦ÓÃÖÐÕ¹ÏÖ³öÓÐÇ°¾°µÄÐÔÄÜ£¬´ÓÄÔÖ×ÁöºÍתÒÆÁö·Ö¸îµ½Ñª¹Ü²¡Àí¼ì²âºÍ¼ø±ðÕï¶ÏÉú³É¡£¶àÖÐÐÄÑéÖ¤Ñо¿ÈÕÒæÖ§³ÖAIÄ£ÐÍ¿çɨÃèÒÇ¡¢ÈËȺºÍÓ°ÏñÐÒéµÄ·º»¯ÐÔ£¬Í¹ÏÔÆäÎȽ¡ÁÙ´²×ª»¯µÄDZÁ¦¡£ÖµµÃ×¢ÒâµÄÊÇ£¬¾¡¹ÜAIÔÚÉñ¾·ÅÉäѧÖпìËÙÔö³¤£¬µ«Ïà¶Ô½ÏÉÙµÄÑо¿Äܳ¬Ô½µ¥ÖÐÐÄ¿ª·¢½øÈëÎȽ¡µÄ¶àÖÐÐÄÑéÖ¤£¬Õâ͹ÏÔÁË·½·¨´´ÐÂÓëÏÖʵÁÙ´²×ª»¯Ö®¼äµÄ¹Ø¼ü²î¾à¡£\n6.1 ¾ÖÏÞÐÔ\nÂ×ÀíÌôÕ½°üÀ¨¼¯ÖÐʽÊý¾ÝϵͳÖеĻ¼ÕßÒþ˽µ£ÓÇ¡¢Ëã·¨ºÍÊý¾Ý¼¯Æ«¼û£¬ÒÔ¼°GDPRºÍHIPAAµÈÊý¾Ý±£»¤¿ò¼ÜÖ´Ðв»Ò»Ö¡£¼¼ÊõºÍ·½·¨¾ÖÏÞÈÔÈ»´æÔÚ£ºµ±Ç°AIÄ£ÐÍÔÚѵÁ··½·¨¡¢Êý¾Ý¼¯×é³ÉºÍÑéÖ¤Ö¸±ê·½Ãæ±íÏÖ³öÒìÖÊÐÔ£»Ðí¶àϵͳȱ·¦¿É½âÊÍÐÔ£¬ºÜÉÙ¿¼ÂÇ»¼Õߺϲ¢Ö¢£¬ÇÒÔÚÓÐÏÞ»òÈË¿Úͳ¼ÆѧÏÁÕµÄÊý¾Ý¼¯ÉÏѵÁ·¡£È±·¦±ê×¼»¯»ù×¼ºÍ¿ÉÖظ´ÐÔÖ¸ÄϽøÒ»²½Ê¹ÁÙ´²ÆÀ¹À¸´ÔÓ»¯¡£±¾×ÛÊö±¾Éí´æÔÚÖØÒª¾ÖÏÞ£º×÷ΪÕë¶ÔÐÔ·¶Î§×ÛÊö£¬²¢·ÇÖ¼ÔÚÇ£¬ÄÉÈëÑо¿ÊýÁ¿Ïà¶Ô½ÏÉÙ·´Ó³ÁËÑϸñÄÉÈë±ê×¼¶Ô¶àÖÐÐÄÑéÖ¤µÄÌض¨¹Ø×¢£»¸÷Ñо¿¶Ô¡°¶àÖÐÐÄ¡±ÑéÖ¤¶¨ÒåµÄ¿É±äÐÔ¿ÉÄܵ¼ÖÂÒÅ©ʹÓöà»ú¹¹Êý¾Ýµ«Î´Ã÷È·ÃèÊöµÄÏà¹ØÎÄÏ×£»Ñо¿Éè¼Æ¡¢Êý¾Ý¼¯ºÍ±¨¸æÖ¸±êµÄÒìÖÊÐÔÏÞÖÆÑо¿¼äÖ±½Ó±È½Ï¡£\n6.2 ¿ÉÀ©Õ¹AIµÄ»ù´¡ÉèÊ©ÓëÕþ²ß\nAIÔÚÉñ¾Ó°ÏñÖеĿÉÀ©Õ¹²¿ÊðÐèÒªÎȽ¡µÄ»ù´¡ÉèÊ©ºÍά»¤¾«ÃܵÄÈíÓ²¼þ¡£ÔÚ»ù´¡²ãÃ棬ÕâЩϵͳÐèÒª±ê×¢Êý¾ÝÀ´²úÉú¹¦ÄÜÐÔѵÁ·Êý¾Ý¼¯£¬ÕâÐèÒªºÏ¸ñҽʦºÍר¼ÒµÄе÷Óë×Éѯ¡£ÔÚ»ú¹¹²ãÃ棬ҽԺ±ØÐëÈ·±£¾ß±¸ÔËÐÐÕâЩģÐ͵ݲȫ¼ÆËãÓ²¼þ£¬°üÀ¨´¦Àí¸ßÐÔÄܼÆËãÈÎÎñµÄ¼ÆËã»ú½ÚµãºÍͼÐδ¦Àíµ¥Ôª£¨Graphics Processing Units, GPUs£©¡£FL»¹ÐèÒªÖÐÑë¾ÛºÏ·þÎñÆ÷½øÐÐе÷ºÍÄ£Ð͸üС£ÕâЩÉ豸ÀíÏëÇé¿öÏÂÓ¦Å䱸Êʵ±µÄÈí¼þ£¬°üÀ¨Êý¾ÝÔ¤´¦Àí¹ÜµÀ¡¢ÐÅÏ¢°²È«µÄ¼ÓÃÜ·½·¨¡¢ÏµÍ³¼ä±£ÃÜÊý¾Ý½»»»µÄ°²È«²ÎÊýÐÒ顣ϵͳ±ØÐë¾ß±¸»¥²Ù×÷ÐÔ¡ª¡ª²»Í¬ÏµÍ³»òÉ豸ͨÐźͽ»»»Êý¾ÝµÄÄÜÁ¦¡ª¡ªÌرðÊÇ´ÓÓ°ÏñÉ豸´«ÊäÊý¾ÝºÍ¿çÖÐÐÄÁ¬½Ó¡£ÕâÇ¿µ÷ÁËʹÓÃҽѧÊý×Ö³ÉÏñºÍͨÐÅ£¨Digital Imaging and Communications in Medicine, DICOM£©±ê×¼½øÐд洢ºÍ½»»»ÐÒéÒÔ¼°Î¬³Ö±ê×¼»¯±ê×¢¿ò¼Ü½øÐÐÊý¾Ý±ê×¢µÄÖØÒªÐÔ¡£Ó²¼þÒìÖÊÐÔÒ²ÒýÈëÁË´àÈõÐÔ£¬Ôì³ÉѵÁ·²î¾àºÍ´ú±íÐÔ²»×㣬Òò´Ë¿çÓ°Ïñģ̬µÄÊý¾Ýе÷£¨ÈçMRIÊý¾Ý¼¯µÄÏñËØÇ¿¶È¹éÒ»»¯¼¼Êõ£©¾ßÓмÛÖµ¡£Õþ²ß¿ò¼ÜͬÑù¹Ø¼ü£¬ÓÃÓÚʵʩ¿ÉÀ©Õ¹Êý¾Ý¼¯µÄÖÎÀí¡¢×ñÊØÒþ˽Á¢·¨ºÍ×ÊÖú¼¼Êõ»ù´¡ÉèÊ©¡£\n6.3 δÀ´¿¼Á¿\nδÀ´Ñо¿Ó¦¾Û½¹¶àģ̬ÕûºÏ£¬½«¶àÖÖÓ°Ïñģ̬£¨ÈçMRI¡¢CT¡¢PET£©ÓëÁÙ´²ºÍÒÅ´«Êý¾Ý½áºÏ£¬ÒÔÌá¸ßÕï¶Ï׼ȷÐÔºÍÇé¾³Àí½â¡£ADNIµÈ¿ª·Å»ñÈ¡Êý¾Ý¼¯Ó¦À©Õ¹ÒÔ½â¾öÊý¾ÝÒìÖÊÐÔ²¢Í¨¹ýÈ«Çò´ú±íÐÔ´Ù½øËã·¨¹«Æ½ÐÔ¡£ÎªÆ½ºâÒþ˽ÓëÐÔÄÜ£¬Áª°îѧϰ£¨FL£©ºÍÎ޼ලÓòÊÊÓ¦£¨Unsupervised Domain Adaptation, UDA£©ÒÑ»ñµÃ¹Ø×¢¡£FLʵÏÖÎÞÐè¹²ÏíÔʼÊý¾ÝµÄÈ¥ÖÐÐÄ»¯Ä£ÐÍѵÁ·£¬¶øUDAÔÊÐíÄ£ÐÍͨ¹ýÀûÓÃÏÈǰѧϰ·º»¯µ½Î´±ê×¢»òÓòÆ«ÒƵÄÊý¾Ý¼¯¡£UDA¿É»º½â¡°ÓòÆ«ÒÆ¡±ÎÊÌ⣬ʹģÐÍÊÊÓ¦ºÍÓÅ»¯µ½¶à¸ö²»Í¬Êý¾ÝÔ´ºÍÓò£¬Ãֺϱê×¢ÄÚ²¿Ô´ÓëÐÂÍⲿ¶ÓÁÐÖ®¼äµÄ²î¾à¡£È»¶ø£¬È¥ÖÐÐÄ»¯¿ÉÄÜ·Å´óÊý¾Ý¼¯±äÒìÐÔ²¢Ê¹ÖÊÁ¿¿ØÖƸ´ÔÓ»¯¡£»¹Ó¦¿¼ÂDZê×¼»¯³ÉÏñÐÒéÒÔÔÚÊäÈë²ãÃæ½â¾ö²»Ò»ÖÂÐÔ¡£ÁíÒ»ÖÖ·½·¨¡ª¡ªÊ¹ÓÃÄäÃû»¯¶à»ú¹¹Êý¾Ý½øÐа²È«¼¯ÖÐѵÁ·¡ª¡ª¿ÉÔÚͨ¹ý±ê×¼»¯Ô¤´¦ÀíºÍÖÊÁ¿±£Ö¤¸ÄÉÆÒ»ÖÂÐÔµÄͬʱ±£³ÖÒþ˽¡£½üÆÚ»¹Ìá³öÁË¡°Áª°îÓòÊÊÓ¦¡±£¬¼´ÑµÁ·Ò»¸öͨÓÃÄ£ÐͲ¢¸¨ÒÔ¸üרҵ»¯µÄÓòµ÷ÓÅ˽ÓÐÄ£ÐÍ£¬ËüÃÇÏ໥½»»¥ÒÔ´ï³É¹²Í¬Êä³ö¡£AIÔÚÉñ¾·ÅÉäѧÖеĸºÔðÈÎÍƽø»¹ÐèÒª¸üÇ¿ÓÐÁ¦µÄ¼à¹ÜºÍÔËÓª¿ò¼Ü¡£HIPAAºÍGDPRµÈÏÖÐз¨ÂÉÌṩÁË»ù´¡Ö¸µ¼£¬µ«Î´Õë¶ÔAIÌØÓÐÌôÕ½½øÐж¨ÖÆ£¬ÌرðÊÇÄ£ÐÍÖØѵÁ·¡¢¿É½âÊÍÐÔºÍÊý¾ÝËÝÔ´¡£ÕâЩ¼à¹Ü·¾¶Í¨³£ÓÅÏÈ¿¼ÂǾ²Ì¬ÑéÖ¤£º²¿ÊðÇ°¶Ô¹Ì¶¨Ä£ÐͽøÐе¥´ÎÆÀ¹À£¬¶øδ¿¼ÂDz¿Êðºó¸üпÉÄܵ¼ÖµÄÐÔÄܱ仯¡£ÕâÒ»¾ÖÏÞ¶Ô²¿Êðºó³ÖÐøѧϰµÄ×ÔÊÊӦģÐÍÓÈΪÖØÒª£¬ÒòΪ³ÖÐø¸üпÉÄÜÎÞ·¨ÔÚ²»Öظ´ÉóÅúÁ÷³ÌµÄÇé¿öÏÂÇáÒ×±»ÈÝÄÉ¡£ÐèÒª¹ú¼ÊºÏ×÷À´Öƶ¨ÃæÏòAIµÄÊý¾ÝÖÎÀíÖ¸ÄϺÍÂ×Àí±ê×¼£¬È·±£»¼Õß°²È«ºÍ»¥²Ù×÷ÐÔ¡£´ËÍ⣬¾¼Ã·ÖÎö¡ª¡ª°üÀ¨Ä£ÐÍѵÁ·¡¢»ù´¡ÉèÊ©ºÍÁÙ´²ÕûºÏ³É±¾¡ª¡ªÓ¦ÎªÕþ²ßºÍ²ÉÄɲßÂÔÌṩÐÅÏ¢¡£×ÝÏò¶àÖÐÐÄÑо¿ÆÀ¹Àʱ¼äЧÂÊ¡¢¿ÉÀ©Õ¹ÐԺͳ¤ÆÚ»¼Õß½á¾Ö¶ÔÓÚÔÚÏÖʵ»·¾³ÖÐÑéÖ¤ÕâЩ¹¤¾ßÖÁ¹ØÖØÒª¡£Ëæ×ÅÁÙ´²Ò½Ê¦¶ÔAIÊìϤ¶ÈµÄÌá¸ß£¬Åàѵ¼Æ»®ºÍ»ú¹¹Ö§³Ö½«È·±£×¼È·½â¶Á²¢¼õÉÙÎóÓá£ËæןßÐÔÄÜAIÄ£ÐÍÈÕÒæÈÚÈëÁÙ´²¹¤×÷Á÷³Ì£¬·ÅÉä¿ÆҽʦµÄ½ÇÉ«¿ÉÄÜ´ÓÖ÷ҪͼÏñ½â¶ÁÕßת±äΪ¸ü¾ß¼à¶½ÐÔµÄλÖ㬳䵱Ëã·¨Êä³öµÄÑéÖ¤Õß¡£\n7 ½áÂÛ\nAIÒѳ¹µ×¸Ä±äÁËÉñ¾Ó°ÏñѧµÄ¸ñ¾Ö£¬ÔÚÕï¶Ï׼ȷÐÔ¡¢¹¤×÷Á÷³ÌЧÂʺÍÁÙ´²¾ö²ßÖ§³Ö£¨CDS£©·½ÃæÌṩÁËÇ°ËùδÓеĽøÕ¹¡£CNN¡¢U-Net±äÌåºÍÐÂÐË»ù´¡Ä£Ð͵ÈDL¼Ü¹¹ÔÚ¶àÖÖÓ°ÏñÈÎÎñÖÐÕ¹ÏÖ³ö׿ԽÐÔÄÜ£¬°üÀ¨²¡Ôî¼ì²â¡¢·Ö¸îºÍÔ¤ºó·ÖÎö¡£È»¶ø£¬°éËæÕâЩ¼¼ÊõÊÕÒæ¶øÀ´µÄÊǸ´ÔÓµÄÂ×Àí¡¢¼à¹ÜºÍʵ¼ùÌôÕ½¡£Êý¾ÝÒþ˽¡¢Ë㷨ƫ¼û¡¢¿É½âÊÍÐԺͲ»¹«Æ½»ñÈ¡µÈÎÊÌâ±ØÐëÔڹ㷺ÁÙ´²ÕûºÏ֮ǰµÃµ½½â¾ö¡£ÎȽ¡µÄÖÎÀí¿ò¼Ü¡¢Í¸Ã÷µÄÑéÖ¤ºÍ°üÈÝÐÔµÄÊý¾Ý¼¯´ú±íÐÔ¶ÔÓÚÈ·±£AIϵͳ°²È«¹«Æ½µØ·þÎñ»¼ÕßÖÁ¹ØÖØÒª¡£ÁÙ´²Ò½Ê¦¡¢Ñо¿ÈËÔ±¡¢¹¤³ÌʦºÍÕþ²ßÖƶ¨ÕßÖ®¼äµÄ³ÖÐøÐ×÷¶ÔÓÚÃֺϴ´ÐÂÓ븺ÔðÈÎʵʩ֮¼äµÄ²î¾àÖÁ¹ØÖØÒª¡£Ëæ×ÅÁìÓò³ÉÊ죬ÖصãÓ¦´Ó¸ÅÄîÑé֤׼ȷÐÔתÏò¿É½âÊÍÐÔ¡¢·º»¯ÐÔºÍÂ×Àí¹ÜÀí¡£Í¨¹ý³ÖÐøµÄ¿çѧ¿ÆºÏ×÷ºÍ¼à¶½£¬AIÔÚÉñ¾Ó°ÏñѧÖв»½öÓÐÍûÌá¸ßÕï¶Ï¾«¶È£¬»¹ÓÐÍûÒÔ¹«Æ½¿ÉÐŵķ½Ê½ÖØж¨ÒåÉñ¾»¤Àí±ê×¼¡£","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-9/20260927000425378.htm","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 14247 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 14247 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":14247,"summary_length":5898,"usable_text_length":14247,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":14247,"summary_length":5898}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}